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1. Introduction 
1.1 Myelodysplastic syndromes 
 Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal bone 
marrow diseases originating from a malignant transformation of multipotent hematopoietic 
stem or progenitor cells (HSPCs). They are characterized by an impaired hematopoiesis 
leading to peripheral blood cytopenia and morphologic dysplasia of hematopoietic cells. 
Of note, patients suffering from MDS have a high risk of disease transformation to acute 
myeloid leukemia (AML) (Arber et al., 2016; Vardiman et al., 2009). 
1.1.1 Epidemiology 
 MDS are a common hematologic malignant disease, especially in the elderly with a 
median age at diagnosis of 71 - 76 years (Ma et al., 2007). Considering all ages, in 
Germany the incidence of MDS is about 4 cases per 100,000 persons per year with a 
prevalence of 7 in 100,000 (Neukirchen et al., 2011). The incidence increases rapidly with 
advancing age, reaching more than 15 - 50 cases per 100,000 in the age group older than 
70 years (Aul et al., 2001). New data estimate the incidence of MDS in the United States 
between 5.3 and 13.1 cases per 100,000, reaching between 75 and 162 cases per 
100,000 in the age group above 65 years (Cogle, 2015). The incidence and prevalence is 
higher among men than women (Aul et al., 2001; Neukirchen et al., 2011). Most likely, the 
incidence of MDS will rise further due to the increasing life expectancy, a greater 
awareness of MDS among physicians, and longer survival of patients with other 
neoplasms after initial treatment placing them at risk for therapy-related MDS (Corey et 
al., 2007; Greenberg et al., 2012; Sperling et al., 2016). Very rarely, pediatric patients are 
affected, most often in association with inherited familial syndromes predisposing to MDS 
and AML, e.g. Fanconi anemia, familial platelet disorder with propensity to myeloid 
malignancy, Shwachman-Diamond syndrome, dyskeratosis congenita or severe 
congenital neutropenia (Corey et al., 2007; Liew and Owen, 2011).  
1.1.2 Pathogenesis and clinical presentation 
 In the pathogenesis of MDS recurrent initiating mutations in HSPCs give rise to 
myelodysplastic stem cells (MSCs). MSCs possess increased self-renewal leading to 
clonal expansion and dominance over normal hematopoietic stem cells (HSCs). The 
acquisition of further cooperating mutations leads to an impairment of terminal maturation 
resulting in an aberrant differentiation process and morphological abnormalities of the 
myeloid hematopoietic cells in the bone marrow, two key characteristics of MDS. 
Consequently, despite an often hyper- or normocellular bone marrow, increased apoptosis 
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of differentiating cells results in an ineffective hematopoiesis with peripheral blood 
cytopenia. Unaffected HSCs can only partially compensate this dysfunction. Thus, MDS 
patients suffer from cytopenia of one or more myeloid lineages. They often present with 
clinical symptoms related to their peripheral cytopenia. For instance, anemia can result in 
symptoms such as fatigue, weakness or angina. Recurrent infections originate from 
neutropenia, while a history of bleeding is common when suffering from thrombocytopenia 
(Corey et al., 2007; Sperling et al., 2016). The peripheral cytopenia can progressively 
worsen during the course of the disease due to the mutation-driven evolution of the 
MSCs. For the individual patient, symptoms strongly depend on the types of mutations 
and the affected myeloid lineages as well as the speed of disease progression (Corey et 
al., 2007).  
1.1.3 Diagnosis and classification 
 Patients can develop MDS either de novo (primary MDS) or therapy-related to 
potentially mutagenic therapy, such as chemo- or radiotherapy (tMDS/secondary MDS), 
then often showing a shorter time to leukemic transformation (Corey et al., 2007). 
According to the World Health Organization (WHO), the diagnosis of MDS requires three 
main criteria: otherwise unexplained cytopenia in one or more myeloid lineages, 
significant morphologic dysplasia and a blast count below 20 % of the total nucleated cells 
in the peripheral blood and bone marrow (Arber et al., 2016). MDS has to be carefully 
distinguished from differential diagnosis that may present with cytopenia and/or dysplasia, 
for instance megaloblastic anemia, aplastic anemia, MDS/MPN overlap syndromes, and 
AML. AML can also develop de novo or on top of a pre-existing hematologic disease, then 
termed secondary AML (sAML), showing a poor therapy response and a worse prognosis. 
MDS and sAML lie along a disease continuum and are mainly separated by the blast 
count. Currently, cases with blast counts above 20 % are defined as AML (WHO 
classification 2008 and 2016). The transformation from MDS to secondary AML is caused 
by clonal evolution of MSCs by accumulation of additional genetic lesions (Sperling et al., 
2016). This development is encountered in about 30 % of MDS patients and severely 
worsens their prognosis (Greenberg et al., 2012).  
 Two prominent classification systems are used to determine the sub-types of MDS: 
the French-American-British (FAB) system, using cytomorphological abnormalities and 
blast percentage (Bennett et al., 1982), and the WHO classification of myeloid neoplasms 
and acute leukemia (Arber et al., 2016). The latter includes important decision criteria 
such as signs of dysplasia and cytopenia, blast proliferation as well as presence of a 
deletion of the long arm of chromosome 5 (Germing et al., 2013). MDS with an isolated 
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deletion of 5q is a separate entity in the WHO classification, termed the “5q - Syndrome”. 
It was first described in 1974 with distinct morphologic features and a rather favorable 
prognosis (Van den Berghe et al., 1974). The revised WHO classification from 2016 
introduces refinements to morphologic criteria and cytopenia assessments. Also, it 
addresses newly described genetic information in MDS diagnosis and classification (Arber 
et al., 2016). In addition, the international prognostic scoring system (IPSS) (Greenberg et 
al., 1997) and the recently revised version (IPSS-R) (Greenberg et al., 2012) are widely 
used for estimation of survival and risk stratification of progression to AML. In the IPSS-R 
a prognostic score ranging from ≤ 1.5 to > 6 is defined according to the cytogenetic risk 
group, blast percentage in the bone marrow, and depth of cytopenia. The prognostic score 
stratifies patients into five different risk groups: very low, low, intermediate, high and very 
high risk. The median survival times range from 8.8 years (very low risk) to 0.8 years (very 
high risk), and the time for progression to sAML for 25 % of the patients from not reached 
(very low risk) to 0.73 years (very high risk) (Greenberg et al., 2012). The discoveries of 
recurrently mutated genes in MDS refine prognostic and diagnostic approaches, thus, 
many medical centers include detailed genetic analysis in their diagnostics to optimize 
their treatment according to the individual patient (Gangat et al., 2016). Recently, large 
scale sequencing studies have revealed that even asymptomatic individuals with a normal 
blood cell count have somatic mutations in MDS-associated genes, leading to a 
predisposition for myeloid malignancies such as MDS, AML or other myeloid neoplasms. 
This disease state has been termed clonal hematopoiesis of indeterminate potential 
(CHIP). It seems comparable to other known clonal pre-malignant disorders such as the 
monoclonal gammopathy of undetermined significance (MGUS) with a risk of progression 
to multiple myeloma. The annual risk for disease progression in the presence of CHIP is 
low at 0.5 to 1 %. Patients can present with cytopenia or without any symptoms at all, but 
they are lacking the morphological criteria for MDS. To date, the significance of screening 
patients for CHIP in order to prevent a possible disease progression remains to be 
determined in further research (Sperling et al., 2016; Steensma et al., 2015). 
1.1.4 Therapy 
 Treatment options for MDS patients are risk-adapted and vary according to the 
clinical problems and the severity of the disease. Low risk patients are observed until 
symptoms appear, followed by best supportive care, treating the leading complaints to 
maintain a good quality of life. This includes blood transfusions, anti-infective therapy and 
stimulation with hematopoietic growth factors. Also, two approved drugs for MDS 
treatment, azacitidine and decitabine, both hypomethylating agents, and enrollment in 
clinical trials using novel drugs are treatment options, if clinical symptoms cannot be 
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controlled. MDS patients with an isolated 5q deletion benefit from a treatment with 
lenalidomide (List et al., 2006), a drug that targets the multifunctional protein cereblon 
(CRBN), an E3 ubiquitin ligase. Lenalidomide increases the CRBN affinity for casein 
kinase 1α (CK1α), resulting in degradation of CK1α. Cells with a 5q deletion have a lower 
level of CK1α than normal HSCs. Thus, the increased degradation by lenalidomide 
pushes CK1α below a certain level inducing cell death by a TP53-dependent mechanism. 
Consequently, TP53 mutations in 5q - Syndromes are an indicator for lenalidomide 
therapy resistance (Kronke et al., 2015). Patients with a higher risk MDS should be 
directly considered for high-dose chemotherapy followed by hematopoietic stem cell 
transplantation (HSCT) for long term remission. In fact, allogeneic HSCT is the only 
available cure for MDS. Unfortunately, due to the high age at diagnosis, associated co-
morbidities and the risks of HSCT itself (e.g. infections, graft versus host disease, disease 
relapse), this treatment can only be offered to few (Gangat et al., 2016). Nevertheless, if 
low risk patients show progression to a higher risk group, e.g. by new cytogenetic lesions 
or severe symptom aggravation, a delayed transplantation approach should be 
considered. Another option for patients not eligible for HSCT is the enrollment in clinical 
trials using novel agents such as inhibitors of histone deacetylases (mocetinostat, 
pracinostat) or kinases (rigosertib, volasertib), rather than treatment with hypomethylating 
agents showing only limited survival benefit (Gangat et al., 2016).  
1.2 Genetics in MDS  
 In contrast to the genomes of other neoplasms, the MDS genome is known to be 
karyotypically normal in about 50 % of all cases. However, chromosomal abnormalities 
have been detected in 50 % of de novo MDS cases using metaphase cytogenetic analysis 
(Haase et al., 2007; Schanz et al., 2012). More sensitive techniques such as single 
nucleotide polymorphism microarrays increased the sensitivity of detection of 
abnormalities up to 80 % (Heinrichs et al., 2009; Tiu et al., 2011). Notably, cytogenetic 
abnormalities in MDS are mostly deletions (Haase et al., 2007), suggesting a frequent 
deletion of tumor suppressor genes rather than oncogene activation. The most frequent 
recurrent isolated cytogenetic deletions in MDS involve deletions of chromosome 5q, 7q 
and 20q (Figure 1).  
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Figure 1: Recurrent cytogenetic abnormalities in MDS. Frequencies of most common 
cytogenetic aberrations in 1084 MDS cases with clonal cytogenetic abnormalities (52 %) from 2072 
MDS cases in total, subdivided into isolated cases with only one anomaly, with one additional 
anomaly or as part of complex anomalies. Figure taken from (Haase et al., 2007). 
 Over the past ten years, technical and scientific advance such as next generation 
sequencing, has led to identification of new molecular abnormalities in MDS (Sperling et 
al., 2016). Recurrent somatic mutations have been identified in over 90 % of patients with 
MDS, including those with a normal karyotype. The most frequently mutated genes are 
involved in RNA splicing (SF3B1, SRSF2, U2AF1, ZRSR2) or epigenetic regulation of 
gene expression (TET2, ASXL1, EZH2, DNMT3A, IDH2). In addition, transcription factors 
such as RUNX1 or TP53 are among the most commonly mutated genes in MDS. Six 
particular genes - TET2, SF3B1, ASXL1, SRSF2, DNMT3A, and RUNX1 - are mutated 
with a frequency of more than 10 % (Figure 2). While many genes have been described to 
be recurrently mutated in MDS, most show a very low mutation frequency (<5 %, Figure 2) 
(Haferlach et al., 2014; Papaemmanuil et al., 2013). 
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Figure 2: Significantly mutated genes in MDS. Frequency of mutations in recurrently mutated 
genes, colors indicating MDS subtype according to the WHO classification of 2008. Figure taken 
form (Haferlach et al., 2014). 
 Interestingly, many of these mutations dictate a specific morphological and clinical 
phenotype (Papaemmanuil et al., 2013). For instance, the SF3B1 mutation status has 
been shown to predict the presence of ringed sideroblasts in the bone marrow and is 
associated with a better overall survival (Malcovati et al., 2011). This finding has recently 
been included into the 2016 revision of the WHO classification of MDS (Arber et al., 
2016). Of note, the described mutations do not occur in an isolated fashion; cells rather 
successively acquire mutations causing disease progression and potentially leukemic 
transformation. In this process, mutations in genes encoding for splicing factors, e.g. 
SF3B1 and SRSF2, and involved in DNA methylation, e.g. DNMT3A and TET2, occur 
very early, whereas mutations in genes for histone modification or signaling occur later 
(Papaemmanuil et al., 2013). Interestingly, the most common mutations in CHIP affect 
DNMT3A and TET2, as well. This might indicate, that some mutations primarily lead to 
CHIP and only after acquisition of additional mutations to MDS, while other initially 
acquired mutations, e.g. in splicing factor genes, directly cause morphologic dysplasia, 
and thus MDS onset (Sperling et al., 2016). The current understanding of cancer 
development suggests that patients with CHIP, showing recurrent MDS-associated 
mutations, represent the initial step of a continuous path of evolution of myeloid 
malignancies, depending on the time of occurrence and frequency of acquired cooperative 
mutations. Early mutations lead to a clonal advantage of malignant hematopoiesis, and 
further accumulation of mutations can lead to the development of dysplasia, low-risk and 
high-risk MDS, and eventually sAML. Consequently, the hierarchy, in which mutations 
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occur, might be useful to predict and monitor progression of the disease (Haferlach et al., 
2014; Papaemmanuil et al., 2013; Sperling et al., 2016).  
 The combination of cytogenetic abnormalities and somatic mutations most likely 
causes the great clinicopathological heterogeneity of MDS (Lindsley and Ebert, 2013) 
represented in the great variety of clinical symptoms and genetic lesions. As a result, the 
number of genetic lesions - cytogenetic aberrations and somatic mutations - correlates 
strongly with the prognosis of the disease and the determination of the exact mutations of 
a patient could allow for more individualized treatment decisions (Haase et al., 2007; 
Haferlach et al., 2014; Papaemmanuil et al., 2013). 
1.2.1 MDS with 20q deletion  
 Cytogenetic abnormalities in MDS are mostly deletions. The long arm of 
chromosome 20 contains a commonly deleted region (CDR) in myeloid malignancies, 
including 2 - 4 % of MDS cases (Figure 1) (Haase et al., 2007)). In MDS an isolated 
del(20q) is associated with fewer bone marrow blasts and a longer survival compared to 
other MDS patients (Braun et al., 2011; Schanz et al., 2012).  
 Certainly, the 20q CDR has been proposed to harbor at least one tumor suppressor 
gene, and efforts have been made to define the CDR and the candidate genes within 
(Bench et al., 2000). Interestingly, the 20q deletion has only been described as 
heterozygous without any evidence for a small deletion within the remaining region of the 
other chromosome and copy neutral loss-of heterozygosity have not been found 
(Heinrichs et al., 2009; Huh et al., 2010). In addition, a point mutation of genes on the 
remaining allele has never been reported. This implicates that the presence of a classical 
tumor suppressor requiring bi-allelic inactivation is very unlikely. Rather, a 
haploinsufficient tumor suppressor gene has been postulated for the del(20q) region that 
is essential for cell viability but has a strongly dose-dependent tumor suppressor function. 
Recently, the transcription factor MYBL2 was identified as such a gene-dosage dependent 
tumor suppressor gene in MDS, located within the 20q CDR (Heinrichs et al., 2013). 
Transcription factors are known to be frequently mutated in myeloid malignancies, 
including MDS. They are proposed to drive the dominance of the mutated clone by 
allowing for aberrant self-renewal and disruption of differentiation in hematopoietic cells 
(Lindsley and Ebert, 2013). Notably, MYBL2 was not only expressed at low levels in 
del(20q) MDS cases but also in MDS cases with a normal karyotype, suggesting 
additional mechanisms of reduction of MYBL2 expression levels (Heinrichs et al., 2013). 
Thus, the downregulation of MYBL2 expression appears to be a more common driver of 
MSCs and is not restricted to patients with 20q deletions. In this context, a competitive 
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bone marrow transplantation assay in mice showed that primary murine bone marrow 
cells with sub-haploinsufficient expression levels of Mybl2 (20 - 30 %) – mediated by RNA 
interference – became clonally dominant and the mice developed myeloid disorders. 
These findings implicate that low levels of MYBL2 gene expression are a central 
mechanism in development of clonal dominance in MDS (Heinrichs et al., 2013). This 
notion is supported by a second independent study showing that classical Mybl2 
haploinsufficiency increased susceptibility to age-related hematopoietic disorders in mice 
(Clarke et al., 2013).  
1.3 MYBL2 
MYBL2 is a member of the highly conserved vertebrate Myb transcription factor 
family, comprising MYBL1 (A-MYB), MYBL2 (B-MYB) and MYB (C-MYB). MYBL2 is 
ubiquitously expressed in all proliferating cells (Nomura et al., 1988), while MYB and 
MYBL1 show rather tissue-specific expression patterns. For instance, the expression of 
MYB is mainly restricted to the small intestine and to hematopoietic progenitor cells, 
playing an important role in the blood cell development (Joaquin and Watson, 2003; 
Westin et al., 1982). Of note, MYB has oncogenic potential (Graf and Beug, 1978). 
MYBL1 is mainly expressed in mitotically active cells during embryogenesis, such as the 
developing central nervous system or spermatogenesis (Joaquin and Watson, 2003; 
Trauth et al., 1994).  
MYBL2 is an essential gene, as bi-allelic inactivation was shown to cause early 
embryonic lethality in mice due to a block in the inner cell mass formation of the blastocyst 
(Tanaka et al., 1999). Further, it is long known to be indispensible for the cell cycle 
progression and therefore its transcription is regulated very tightly. MYBL2 expression is 
upregulated by an E2F-dependent mechanism in the late G1 phase with a peak during the 
S phase of the cell cycle (Lam et al., 1995; Lam et al., 1992), where it regulates the 
transcription of genes required for the G2/M phase transition. Specifically, MYBL2 and the 
MuvB-protein complex, encompassing LIN9, LIN37, LIN52, LIN54 and RBBP4, were 
found to target gene promoters upon recruitment of FOXM1 during the late S phase, and 
thus activate the transcription of G2/M phase genes (Sadasivam et al., 2012). In detail, 
the DREAM complex, comprising the Rb-like protein p130, E2F4, DP1 and the MuvB-
protein complex, represses gene expression of early and late cell cycle genes in the G0 
phase of the cell cycle (Litovchick et al., 2007). Among these genes is MYBL2. Upon cell 
cycle entry, the MuvB-protein complex dissociates form p130/DREAM, resulting in the 
release of the DREAM-complex from cell cycle regulated promoters. Activator E2F 
proteins can then bind to the promoters of early cell cycle genes with a peak expression 
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during G1/S phase and, among others, MYBL2 transcription is initiated (Takahashi et al., 
2000). During the S phase MYBL2 is bound by the MuvB-protein complex and together, 
as MYBL2-MuvB complex, they activate transcription, upon recruitment of FOXM1 to 
promoters of late cell cycle genes. Among these G2/M phase genes are long known 
MYBL2 target genes, such as CCNB1 and CDK1 (Zhu et al., 2004). Interestingly, MYBL2 
and FOXM1 share several target genes, such as CCNB1, PLK1 and Aurora kinase A 
(AURKA), while FOXM1 itself is a target gene of MYBL2 (Sadasivam et al., 2012). The 
MYBL2 activity in the late G1/S phase is controlled by phosphorylation by the cyclin 
A/Cdk2 complex (Joaquin and Watson, 2003; Robinson et al., 1996). Also, poly 
ubiquitination and the subsequent proteasome-mediated degradation, responsible for the 
fast decrease of MYBL2, are regulated by phosphorylation (Charrasse et al., 2000). Due 
to the phosphorylation mediated proteasome degradation in the late S phase, MYBL2 
dissociates from the complex with the MuvB-protein complex and FOXM1, while they in 
turn stay bound to the promoters until late G2 phase (Sadasivam et al., 2012).  
In addition, MYBL2 appears to play a role in the correct formation of the mitotic spindle 
(Yamauchi et al., 2008), and, it might be important for S phase promotion independent 
from its DNA-binding activity (Werwein et al., 2012).  
Most recently, MYBL2 has been discovered as a sub-haploinsufficient tumor 
suppressor in MDS, promoting expansion of hematopoietic progenitors cells at a strangely 
reduced gene dosage (Heinrichs et al., 2013). This finding was independently confirmed 
using haploinsufficient, i.e. heterozygous knockout, mice. Specifically, Mybl2 expression 
levels of 50 % led to the occurrence of hematologic disorders, including MDS, in aged 
Mybl2 haploinsufficient mice (Clarke et al., 2013). Both studies supported early hints 
obtained in a zebrafish screen that a gene dosage reduction of Mybl2 results in the loss of 
a tumor suppressor function (Shepard et al., 2005). In contrast, previous studies reported 
high MYBL2 expression levels in solid tumors associated with poor prognosis (Thorner et 
al., 2009). However, an oncogenic role for MYBL2 has never been demonstrated in 
functional experiments. Thus, while its tumor suppressor activity has been shown in 
functional assays, MYBL2 upregulation appears to be rather a consequence of an 
enhanced proliferation due to unrelated oncogenic mutations. 
1.3.1 Gene dosage insufficiency of tumor suppressor genes 
In the pathogenesis of malignant neoplasms, partial and complete loss of tumor 
suppressor gene expression has been investigated for many years and different 
paradigms of inactivation have been identified. The classical “two-hit” model of 
tumorgenesis requires a bi-allelic inactivation of a tumor suppressor gene in order to allow 
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for a malignant transformation of a cell, i.e. a complete loss of the tumor suppressor 
function. This has been shown for one of the most well-known tumor suppressor genes: 
RB1. Thus, a homozygous inactivation of the RB1 gene is required for retinoblastoma 
development (Figure 3, left) (Berger et al., 2011; Friend et al., 1986; Knudson, 1971). 
However, in other instances a mono-allelic inactivation leading to haploinsufficiency of a 
tumor suppressor gene can also drive cells towards malignancy. A very prominent tumor 
suppressor gene, acting as a tumor suppressor with gene-dosage dependency starting at 
a haploinsufficient level, is TP53 (Figure 3, middle). A reduced TP53 gene dosage, due to 
germline mutations, is found in individuals with the inherited familial cancer syndrome Li-
Fraumeni (Lynch and Milner, 2006). Other cancer susceptibility genes, such as BRCA1 in 
breast cancer (Bellacosa et al., 2010), PAX5 in acute lymphoblastic leukemia (Mullighan 
et al., 2007), APC in intestinal carcinoma (Amos-Landgraf et al., 2012), and RUNX1 in 
AML (Song et al., 1999), have been shown to support neoplastic transformation by their 
heterozygous inactivation. Only recently, the understanding of cancer initiation by loss of 
tumor suppressor function has extended from discrete changes to a continuum model of 
gene dosage dependency of tumor suppressor gene expression (Berger et al., 2011). In 
this model, subtle changes to the expression level of a tumor suppressor can support 
tumorgenesis. In special cases, a complete loss of the tumor suppressor is not compatible 
with cell survival (Figure 3, right), leading to a so-called obligate haploinsufficiency of the 
tumor suppressor gene. This has been exemplified for PTEN in breast cancer (Alimonti et 
al., 2010), and in myeloid malignancies it could be shown for MYBL2 (Figure 3, right) 
(Heinrichs et al., 2013), and SFPI1 (Rosenbauer et al., 2004). 
 
Figure 3: Concepts of tumor suppressor gene inactivation. Left: bi-allelic inactivation leads to 
loss of the tumor suppressor function, example RB1; middle: haploinsufficiency can drive cells 
towards malignancy, example TP53; right: gene dosage levels below haploinsufficiency increase 
tumor susceptibility, while bi-allelic inactivation leads to cell death, example MYBL2. Figure 
adapted from (Berger et al., 2011), including results from (Heinrichs et al., 2013). 
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1.4 Fucci - Fluorescent ubiquitination-based cell cycle indicator 
The Fucci technique marks cells according to their cell cycle phase in a different 
fluorescent color. It takes advantage of two anti-phase oscillating protein levels marking 
cell cycle transitions: Cdt1 and Gmnn (Geminin) (Sakaue-Sawano et al., 2008).   
These two proteins are very important for the cell cycle regulation as they are 
involved in licensing the replication origin (Nishitani et al., 2000). Their levels oscillate 
reciprocally during the cell cycle due to proteolysis induced by the E3 ligase complexes 
APCCdh1 and SCFSkp2. SCFSkp2 is a substrate of APCCdh1 but also a feedback inhibitor, thus 
their activities also oscillate reciprocally during the cell cycle (Nakayama and Nakayama, 
2006). The APCCdh1 complex is active in the M/G1 phase, while the SCFSkp1 complex is 
mostly active in the S/G2 phase. Consequently, protein levels of Cdt1, a direct target of 
the SCFSkp1 complex, are highest in the G1 phase, while Geminin, being controlled by the 
APCCdh1 complex, accumulates in the S/G2/M phase (Figure 4 A) (Nishitani et al., 2004)). 
In the Fucci technique, a truncated version of the human cell cycle proteins Cdt1 and 
Geminin is fused to a fluorescent protein (Figure 4 C). In the original version, Fucci, Cdt1 
is fused to mKO2 (mKO2-hCdt1(30/120)) and Geminin to mAG (Karasawa et al., 2003); 
mAG-hGem(1/110)), leading to a different fluorescence of cells depending on their cell 
cycle phase. Cells fluoresce red in the G1 phase and green in the S/G2/M phase of the 
cell cycle, while at the onset of S phase protein levels overlap and cells fluoresce yellow. 
After cell division a short time span without fluorescence can be observed (Figure 4 B) 
(Sakaue-Sawano et al., 2008). 
These fluorescent cell cycle indicators, allow for the possibility of an unperturbed 
cell cycle phase detection by flow cytometry and separation by fluorescent activated cell 
sorting (FACS) (Figure 4, D and E). In an improved version, “Fucci2”, mKO2 and mAG 
were substituted by mCherry (Shaner et al., 2004), mCherry-CDT1(30/120), and Venus 
(Nagai et al., 2002), Venus-GMNN(1/110), marking cells bright red in the G1 phase and 
green in the S/G2/M phase of the cell cycle with an orange overlap at the onset of S 
phase (Figure 4 C) (Sakaue-Sawano et al., 2011). 
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Figure 4: Fucci technique. (A) Cell cycle regulation by E3 ligases ACP
Cdh1
 and SCF
Skp2
. (B) Cell 
cycle indicators label nuclei depending on their cell cycle phase. (C) Final constructs for Fucci2. (D) 
Flow cytometry of cells expressing Fucci2. (E) Flow cytometry analysis of Fucci2 expressing cells 
stained with Hoechst. (A) and (B) taken from (Sakaue-Sawano et al., 2008), (C) to (E) taken from 
(Sakaue-Sawano et al., 2011). 
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1.5 Aim of this thesis 
 To date, the molecular mechanism of HSPC expansion by reduced MYBL2 levels is 
undiscovered. Interestingly, while a complete inactivation of Mybl2 leads to cell death 
(Tanaka et al., 1999), Mybl2 promotes cell expansion at an expression level of 30 - 50 % 
in a gene dosage dependent manner (Heinrichs et al., 2013). I propose that Mybl2 target 
genes are differentially affected by the downregulation of Mybl2 levels to sub-
haploinsufficiency, possibly due to low and high affinity binding sites. Consequently, the 
expression of target genes with low affinity binding sites would be affected strongly by the 
downregulation of Mybl2, resulting in the loss of the tumor suppressor function of Mybl2 
and allowing for clonal HSPC expansion. In contrast, the expression level of target genes 
with high affinity binding sites would be just marginally reduced, representing the subset of 
target genes required for cell cycle progression and cell survival. As Mybl2 is indispensible 
for the cell cycle progression and its activity strictly depends on the cell cycle phase, 
differences in target gene expression levels will also be cell cycle-dependent. Thus, to 
identify such differentially regulated genes, gene expression profiling with cell cycle 
phase-resolution would strongly improve the determination of significant Mybl2-dependent 
gene expression differences. 
 In order to test this hypothesis, I aimed to establish a system that allows for the 
analysis of cell cycle phase-dependent gene expression profiling in immortalized primary 
murine hematopoietic cells. I intended to implement a cell cycle analysis of murine HSPCs 
based on the Fucci2 technique. To modulate Mybl2 expression levels, I used RNA 
interference, a technique to knockdown expression of specific genes by expression of a 
short hairpin RNA (shRNA) via lentiviral vector transduction. Specifically, I introduced a 
Mybl2-targeting shRNA in an inducible expression vector system to reduce the Mybl2 
expression level to sub-haploinsufficiency. In the described system, I sought to determine 
the expression differences of candidate target genes for the Mybl2 tumor suppressor 
function with cell cycle phase-resolution, comparing cells with regular Mybl2 levels to cells 
with an induced knockdown of Mybl2 expression to sub-haploinsufficiency. 
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2. Material and methods 
2.1 Materials 
2.1.1 Chemicals and reagents 
All chemicals and reagents were purchased from Sigma Aldrich (St. Louis, MO, 
USA) and Carl Roth (Karlsruhe), if not stated otherwise.  
2.1.2 Enzymes and standards 
 All enzymes and their buffers were purchased from Thermo Fisher Scientific 
(Waltham, MA, USA), if not stated otherwise. RNase A (100 mg/ml) and Proteinase K 
solution were purchased from Qiagen (Hilden); rAPid Alkaline Phosphatase was 
purchased from Roche (Basel, Switzerland); AmpliTaqGold DNA Polymerase, 
LifeTechnologies (Carlsbad, CA, USA); GeneRuler 1 kb and 100 bp, Thermo Fisher 
Scientific (Waltham, MA, USA).  
2.1.3 Reagent systems (kits) 
 The QIAquick Gel Extraction kit, the QIAquick PCR Purification kit, the QIAprep Spin 
Miniprep kit, the QIAamp DNA Mini kit and the QuantiTect Reverse Transcription kit were 
purchased from Qiagen (Hilden); the Rapid DNA Ligation kit, Thermo Fisher Scientific Inc. 
(Waltham, MA, USA); CellTiter-Glo Luminescent Cell Viability assay, Promega (Fitchburg, 
WI, USA); Lineage Cell Depletion kit, mouse, Miltenyi Biotec (Bergisch Gladbach). 
2.1.4 Antibodies 
 Lineage Cell Detection Cocktail - Biotin, mouse, Miltenyi Biotec (Bergisch 
Gladbach), containing biotin-conjugated monoclonal antibodies against CD5, CD11b, 
CD45R, Gr1 (Ly6G/C), and Terr-119.  
 Anti-mouse Ly-6A (Sca1) PE-Cy7 (clone D7), anti-mouse CD117 (c-Kit) APC (clone 
2B8), anti-mouse CD11b APC (clone M1/70), anti-mouse Ly-6G eFluor 450 (clone RB6-
8C5), anti-mouse CD45R (B220) PE-Cy 7(clone RA3-6B2), anti-mouse CD3e PerCP-Cy 
5.5 (clone 145-2C11), anti-mouse CD34 FITC and Brilliant Violet (clone RAM34) were 
purchased from eBioscience (San Diego, CA, USA); BD Pharmingen anti-mouse CD16/32 
PerCP-Cy 5.5 (clone 2.4G2) was ordered from BD Bioscience (San Jose, CA, USA); Anti-
Biotin PE, Miltenyi Biotec (Bergisch Gladbach); Streptavidin APC-eFluor 780, eBioscience 
(San Diego, CA, USA). 
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2.1.5 Buffers and solutions 
MACS buffer: PBS supplemented with 0.5 % BSA (bovine serum albumin) and 
2 mM EDTA. The buffer was degassed and kept at 4 °C. 
TAE buffer 50x: 24.2 % Tris, 5.71 % glacial acedtic acid, 0.05 M Na2-EDTA; pH 8.5. 
6x loading dye: 10 mM Tris-HCl, 0.005 % SDS, 60 mM EDTA, 60 % glycerol, 
0.03 % xylene cyanol FF. 
LB medium: 16 g tryptone, 8 g yeast extract, 8 g NaCl in 1 liter distilled water. 
The LB medium was used for agar plates as well and was prepared 
by adding 6 g agar and 300 ml water to 100 ml LB medium. 
PBS: DPBS - Dulbecco‟s Phosphate-Buffered Saline (without CaCl2 and 
MgCl2), Life Technologies (Carlsbad, CA, USA). 
PI staining solution:  0.2 % sodium citrate, 0.05 mg/ml propidium iodide, 0.1 % Triton X -
100 and 0.2 mg/ml RNase A. 
2.1.6 Oligonucleotides 
 All oligonucleotides were ordered from Eurofins MWG Operon (Ebersberg). A 
detailed list of primer sequences is enclosed in the appendix. 
2.1.7 Cell culture material 
 Cell culture material was purchased from Greiner Bio-One (Kremsmuenster), if not 
stated otherwise. Fetal Bovine Serum (Biochrome FBS Gold) was purchased from 
Biochrome (Berlin). Horse serum and Trypsin-EDTA Solution were purchased from Sigma 
Aldrich (St. Louis, MO, USA). HEPES Buffer Solution 1 M, Penicillin/Streptomycin 
10,000 U/ml and L-glutamine 200 mM, all from LifeTechnologies (Carlsbad, CA, USA), 
were used in all cell culture experiments. 
Cell culture media: 
 DMEM - Dulbecco‟s Modified Eagles Medium (1x) - high glucose (4,5 g/l D-Glucose) 
and RPMI Medium 1640 (1x) with L-glutamine were purchased from Life Technologies 
(Carlsbad, CA, USA); IMDM - Iscove‟s Modified Dulbecco‟s Medium - without L-glutamine, 
with 25 mM HEPES, and X-Vivo 15 chemically defined, serum-free hematopoietic cell 
medium without Gentamicin and Phenol Red, were purchased from Lonza (Basel, 
Switzerland). 
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Cytokines:  
All cytokines used (recombinant murine IL-3, recombinant mFlt3 ligand, recombinant 
mTpo (murine thrombopoetin), recombinant mScf (murine stem cell factor)) were obtained 
from PeproTech GmbH (Hamburg). 
2.1.8 Mice 
 Wild-type mice (C57BL/6) were provided by the animal facility of the University 
Hospital Essen. Transgenic mice expressing rtTA (reverse tetracycline-controlled 
transactivator) and a puromycin resistance gene were kindly provided by Prof. Dr. Andrea 
Vortkamp and were originally obtained from the Jackson Laboratory (R26 M2-rtTA) 
(Hochedlinger et al., 2005). 
2.1.9 Laboratory material 
Eukitt quick-hardening mounting medium (Fluka Analytical, St. Gallen, Switzerland); 
Syringe filters 0.2 µm (Minisart, Sartorius AG, Göttingen); Syringe 50 ml (Braun, 
Melsungen); 40 µm Cell Strainer (BIOLOGIX Research, Münster); ACK lysing buffer 
(Lonza, Basel, Switzerland); BD FACS Accudrop Beads (BD Bioscience, San Jose, CA, 
USA); Microscope slides (Marienfeld-Superior, Lauda Könighofen); Cover slips (Roth, 
Karlsruhe); Shandon EZ Single Cytofunnels (Thermo Fisher Scientific, Waltham, MA, 
USA); Sterile pipette tips (Biozym, Hessisch Oldendorf); Ultracentrifugation tubes 
(Beckman Coulter, Krefeld); Pipettes (Gilson Inc., Middleton, WI, USA); BD Falcon tubes 
(BD Bioscience, San Jose, CA, USA). 
2.1.10 Laboratory devices 
Flow cytometers:  FACS Aria I and III, BD Bioscience (San Jose, 
 CA, USA); Cytomics FC 500 Flow Cytometer and 
 Cytoflex, Beckman Coulter (Krefeld)  
Luminometer:  Glomax Multi Detection System, Promega,
 (Fitchburg, WI, USA)  
Spectophotometer:  Nano Drop 2000 Thermo Scientific (Waltham, 
 MA, USA) 
Agarose gel documentation system:  Biozym Scientific GmbH (Hessisch Oldendorf) 
Centrifuges:  Eppendorf (Hamburg)  
Ultracentrifuge: Optima L-80XP Ultracentrifuge, Beckman 
 Coulter (Krefeld)  
Laminar flow hood:  HERAsafe HS12, Heraeus, Thermo Scientific 
 (Waltham, MA, USA) 
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37 °C Incubator:  MaxQ 6000 Orbital Shaker, Thermo Scientific 
 (Waltham, MA, USA)  
CO2 incubator:  HERAcell 240i, Thermo Scientific (Waltham, MA, 
 USA) 
Thermal Cycler:  CFX96 Real Time System C1000, Bio-Rad 
 Laboratories, Inc. (Hercules, CA, USA); PTC 200 
 Thermal Cycler, MJ Research (Waltham, MA, 
 USA) 
Microscopes:  Olympus CKX41, Olympus Corporation 
 (Shinjuku, Tokyo, Japan); Axio Vert.A1, Carl 
 Zeiss GmbH (Jena)  
Cytospin: Shandon Cytospin II, Thermo Scientific 
 (Waltham, MA, USA)  
Cell Counter:  Sysmex XP-300 Automated Hematology 
 Analyzer, Sysmex (Norderstedt); Neubauer 
 counting chamber, Marienfeld-Superior (Lauda 
 Königshofen) 
Heating block: Block Heater HX-1, Peqlab Biotechnologies 
 (Erlangen) 
Electrophoresis chamber: Peqlab Biotechnologies (Erlangen)  
Vortex-Schüttler: VV 3,VWR (Darmstadt) 
2.2 Methods 
2.2.1 Flow cytometry 
Flow cytometry allows the measurement and the analysis of molecular and physical 
properties of a large number of cells on a single cell basis. In the flow cytometer, cells 
separated by a fluidic stream pass a laser beam as single objects and the laser light is 
scattered. The cell size can be estimated by the light that scatters axial to the laser beam 
(forward scatter (FSC)), while the light that scatters perpendicular to the laser beam (side 
scatter (SSC)) allows an assessment of the cells granularity. Additional properties can be 
analyzed by staining the cells with fluorochrome-conjugated antibodies against surface 
antigens (e.g. immunophenotyping) or intracellular components. Also, the expression of 
fluorescent proteins (e.g. green fluorescent protein (GFP)) can be detected by the emitted 
fluorescence. Dyes that fluoresce upon DNA binding can be used to determine the DNA 
content of a cell for cell cycle analysis. Some flow cytometers can sort single cells and cell 
populations according to their properties as predefined by the user‟s sort criteria 
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(fluorescent activated cell sorting (FACS)). In the cell sorter, a droplet from the stream 
containing the cell of interest is electrostatically charged. This charged droplet is then 
deflected to the right or left by charged deflection plates into a collection tube or plate. 
Uncharged droplets are directed into the waste. The process of cell sorting allows a highly 
effective purification of cells and permits to further analyze the sorted subpopulations.  
2.2.1.1 Immunophenotyping 
Fluorochrome-conjugated antibodies directed against surface antigens were used to 
determine the phenotype of isolated murine bone marrow cells in culture 
(immunophenotyping). Based on expression of characteristic lineage markers, 
hematopoietic stem and progenitor cells (lineage-negative) can be distinguished from 
differentiated cells that are positive for at least one marker (lineage-positive). To 
discriminate lineage-positive from lineage-negative cells, cells were stained with a mixture 
of biotin-conjugated monoclonal antibodies against CD5, CD11b, CD45R, Gr1 (Ly6G/C), 
and Terr-119 (Lineage Cell Detection Cocktail - Biotin, mouse (Miltenyi Biotec, Bergisch 
Gladbach)). Labeling was performed in 100 µl MACS buffer for 20 min at 4 °C in the dark, 
using 10 µl cocktail per 106 cells. In a second step a streptavidin conjugated fluorochrome 
(Streptavidin APC-eFlour 780, eBioscience, San Diego, CA, USA) was used to detect the 
biotinylated antibodies. The cells were washed in MACS buffer after every step. To further 
identify specific cell populations, the following anti-mouse antibodies (eBioscience, San 
Diego, CA, USA) were used (clone in parentheses): Ly-6A/Sca1 (D7), CD117/Kit (2B8), 
CD11b/Mac1 (M1/70), Ly-6G/Gr1 (RB6-8C5), CD45R/B220 (RA3-6B2), CD3e (145-
2C11), CD34 (RAM34) and CD16/32 (2.4G2; BD Bioscience, San Jose, CA, USA). If not 
stated otherwise, cells were stained in 100 µl MACS buffer for 30 min at 4 °C in the dark 
with a titrated amount of antibody and washed in MACS buffer afterwards. For flow 
cytometry measurements, the stained cells were re-suspended in 200 - 800 µl of MACS 
buffer. 
2.2.1.2 Fluorescent activated cell sorting and single cell sorting 
Cell sorting was performed on the FACS Aria I or III instrument (BD Bioscience). 
The instrument was calibrated with BD FACS Accudrop Beads (BD Bioscience, San Jose, 
CA, USA). All sort experiments were done with a 100 µm nozzle, and up to four different 
cell populations were sorted in parallel. After every sort, a re-analysis of an aliquot of the 
sorted cells was performed to ensure the purity of the sorted cell population. The cells 
were sorted into cell culture medium. For molecular analysis, they were spun down 
(300 g, 5 min) immediately after the sort and were either re-suspended in TRIzol (Life 
Technologies, Carlsbad, CA, USA) for subsequent RNA extraction or propidium iodide 
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staining solution for cell cycle analysis (2.2.1.3). Cells for cell culture experiments were 
also spun down but were re-suspended in freshly prepared cell culture medium. To 
generate clonal cell populations, single cells were sorted into 96-well plates. This special 
sort setting allows depositing only one cell into each well of the plate. To prevent bacterial 
contaminations, all media for cells used in further cell culture experiments were supplied 
with antibiotics (10,000 U/ml Pen/Strep, LifeTechnologies, Carlsbad, CA, USA). 
2.2.1.3 Cell cycle analysis 
The Cytomics FC 500 flow cytometer (Beckman Coulter) and the Cytoflex (Beckman 
Coulter) were used for cell cycle analysis measuring the cellular DNA content upon cell 
staining with propidium iodide staining solution. Propidium iodide (PI) is a DNA 
intercalating molecule that shows an increase in fluorescence upon binding to DNA. The 
amount of nucleic acid bound propidium iodide is proportional to the DNA content of a cell. 
As cells duplicate their DNA in the S phase of the cell cycle, a cell in the G2 phase 
contains a double amount of DNA compared to a cell in the G1 phase. Thus, the 
measurement of the propidium iodide intensity allows generating a cell cycle profile of cell 
populations. The PI staining solution (2.1.5) was freshly prepared prior to each cell cycle 
analysis. Before the measurement, 100,000 cells were centrifuged and re-suspended in 
250 µl staining solution. Upon incubation for at least 45 min in the dark and at room 
temperature, flow cytometric analysis was performed. The recorded events were 
discriminated for cell doublets or clusters (Figure 5). The exclusion of doublets is 
important as for example two cells in the G1 phase have the same DNA content as one 
cell in the G2 phase of the cell cycle and if stuck together the recorded cell cycle profile 
would be falsified. 
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Figure 5: Flow cytometric gating strategy for the cell cycle analysis of cells stained with PI-
staining solution. Discrimination of debris was performed according to FSC and SCC parameters, 
followed by fluorescence height (PI-height) and area (PI-area) analysis to discriminate doublets, as 
well. In this example PI-stained EML cells were used.  
2.2.2 Preparation of murine bone marrow cells and lineage cell depletion 
Mice were sacrificed, and femur and tibia were dissected. The bones were crushed 
in a mort after removing muscle and connective tissue. Bone marrow cells were 
suspended in MACS buffer and filtered to remove clumps and bone particles (40 µm cell 
strainer, BIOLOGIX Research, Münster). The erythrocytes were lysed with ACK lysing 
buffer (Lonza, Basel, Switzerland). The lineage-negative cells were enriched by magnetic 
cell sorting using the Lineage Cell Depletion kit, mouse (Miltenyi Biotec, Bergisch 
Gladbach). For the depletion of the mature hematopoietic cells, the isolated bone marrow 
cells were magnetically labeled with biotinylated antibodies against lineage markers (CD5, 
CD45R, CD11b, Gr1, Ter-119, 7-4) and with anti-biotin microbeads as a secondary 
labeling reagent. While the unlabeled lineage-negative cells can pass through a magnetic 
field, the magnetically labeled mature cells are retained. This procedure leads to an 
enrichment of “untouched” lineage-negative cells. All labeling and separation steps were 
performed according to the manufacturer‟s protocol. The purity of the enriched lineage-
negative cells was validated by flow cytometry  using aliquots of the separated cell 
fractions stained with anti-biotin PE (Miltenyi Biotec, Bergisch Gladbach), 10 µl antibody 
for up to 107 cells (Figure 6, A to D). Thus, the relative amount of remaining mature 
hematopoietic cells (PE positive) in the enriched lineage-negative cell fraction could be 
determined (Figure 6, D). Usually, starting with about 5 to 10 % of lineage negative cells 
an enrichment up to 95 % was reached. After enrichment, lineage-negative cells were 
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cultivated in X-Vivo 15 medium supplemented with cytokines (80 ng/ml mScf, 40 ng/ml 
mTpo, 40 ng/ml mFlt3 ligand), 100 U/ml Pen/Strep, 2 mM L-glutamine and 10 % heat 
inactivated fetal bovine serum for 24 h. 
 
Figure 6: Analysis of the purity of the lineage-negative enriched bone marrow cells from 
mice (A) As a control isolated, unstained, full bone marrow cells were analyzed after erythrocyte 
lysis. (B) Control cells stained with anti-biotin PE to mark the mature cell fraction (83 %). (C) 
Depleted mature hematopoietic cells. (D) Lineage negative enriched bone marrow cells: 17 % of 
lineage negative cells (PE
neg
 in B) were enriched to 87 %. In this example bone marrow cells 
isolated from M2-rtTA mice were analyzed. 
2.2.3 Polymerase Chain Reaction (PCR) 
PCR is used to amplify a specific DNA sequence and allows for the introduction of 
new sequences, e.g. restriction sites and mutations, into the DNA of interest. A standard 
PCR includes the denaturation of the template DNA, the annealing of the primers 
(oligonucleotides that are complementary to one of the respective strands of the template 
DNA) and the extension of the primers at their 3‟ end by a heat-stable DNA Polymerase 
using deoxynucleoside triphosphates (dNTPs). These steps are repeated in cycles in 
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order to exponentially amplify the target sequence (amplicon) and to generate sufficient 
amounts of DNA for detection or cloning. 
A standard PCR assay included 0.5 µM reverse and forward primer each (Eurofins 
Genomics, Ebersberg), 1 ng template (plasmid or PCR product), 0.2 mM dNTPs (Thermo 
Scientific, Waltham, MA, USA), 1x Phusion High-Fidelity buffer (Thermo Scientific, 
Waltham, MA, USA) and 1 U High-Fidelity Phusion Hot Start II DNA polymerase (Thermo 
Scientific, Waltham, MA, USA). Reactions were performed in 25 - 100 µl volume 
depending on the amount of product needed for subsequent experiments. A table of 
primer sequences is enclosed in the appendix. 
If not stated otherwise, the standard PCR procedure was performed with a PTC-200 
Thermal Cycler (MJ Research, Waltham) using the following program steps:  
1. Initial denaturation  98 °C for 30 sec 
2. Denaturation  98 °C for 10 sec  
3. Annealing   50 °C to 65 °C for 30 sec (temperature depending on 
    primer pair) 
4. Extension    72 °C for 15 - 30 sec/1 kb of amplicon 
5. Repetition of step 2 to 4 between 25 to 35 cycles depending on amount of input 
DNA 
6. Final extension  72 °C for 10 min 
 
2.2.3.1 Fusion PCR 
This special type of PCR allows the fusion of two independent DNA fragments. First, 
the two DNA fragments of interest are amplified separately in two regular PCRs (Figure 7, 
1. and 2.). However, the reverse primer of DNA fragment 1 and the forward primer of DNA 
fragment 2 are designed with an identical sequence that is introduced into both PCR 
products (Figure 7, red label). In a third PCR (Figure 7, 3.), these products are used as 
templates that are amplified with primers complimentary to the ends of the desired full-
length product (forward primer of DNA fragment 1 and the reverse primer of DNA 
fragment 2; Figure 7, A and B), as the identical sequences of the two templates overlap in 
the annealing step. The product of this third PCR amplification is a fused DNA sequence 
that can be used for cloning. The program steps and the PCR reactions were performed 
as described above (2.2.3).  
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Figure 7: Fusion PCR. Two regular PCR amplifications (1. and 2.), primers C and D introduce an 
identical sequence (red) into both products. In a third PCR (3.), the identical sequences overlap, 
and the desired full-length product is amplified with primers A and B (green). 
2.2.4 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to confirm a successful PCR amplification 
(analytical gel) or to purify DNA fragments (preparative gel). A 1 - 2 % agarose (Sigma 
Aldrich, St. Louis, MO, USA) gel was prepared depending on size of DNA fragments to be 
separated. The appropriate amount of agarose was heat-dissolved in 1x TAE buffer 
(2.1.5). After cooling to 50 - 60 °C, ethidium bromide (0.07 %, inno-train diagnostics 
GmbH, Kronberg), a DNA intercalator allowing the detection of DNA, was added and the 
gel was casted. Prior to loading the gel, DNA samples were mixed with a 6x DNA loading 
dye (2.1.5). A standard molecular weight marker (GeneRuler 1 kb or 100 bp, Thermo 
Scientific, Waltham, MA, USA) was loaded in parallel and used to estimate the size of 
DNA fragments. The gels were run in 1x TAE-buffer at 90 - 120 V for 45 - 60 min. In case 
of a preparative gel, the desired DNA gel fragments were cut out with a scalpel. 
2.2.5 DNA purification 
PCR products larger than 100 bp were purified using the silica-membrane-based 
column purification (QIAquick PCR Purification kit, Qiagen, Hilden). The nucleic acids are 
adsorbed to the silica membrane in presence of a high concentration of chaotropic salts 
allowing to remove unwanted contaminants. After several washing steps the pure DNA is 
eluted by a salt-free buffer (10 mM Tris-Cl, pH 8.5). All steps were performed according to 
the manufacturer‟s instructions. Purification of DNA bands in agarose gel was achieved 
using the QIAquick Gel Extraction Kit (Qiagen, Hilden). In a first step, the agarose block 
Material and methods 
30 
 
containing the DNA was solubilized with an agarose-dissolving buffer (Qiagen, Hilden) at 
50 °C for 10 min followed by the silica-based column purification as described. 
2.2.6 Determination of nucleic acid concentration 
The concentration and the purity of nucleic acids (RNA and DNA) were determined 
with a spectrophotometer (NanoDrop 2000, ThermoScientific, Waltham, MA, USA). 
Spectrophotometric quantitation of nucleic acids is based on the absorption of UV-light at 
260 nm (absorption maxima). The Lambert Beer‟s law allows correlating the amount of 
absorbed UV-light to the concentration of nucleic acid in the sample. Thus, the more light 
is absorbed, the higher is the concentration of nucleic acids in the sample. The conversion 
factor for DNA is 50 µg/ml per absorption unit, for RNA this factor is 40 µg/ml. As proteins 
have their absorption maxima at 280 nm, the ratio of absorption at 260 nm to the 
absorption at 280 nm is used to assess contaminations of the nucleic acid samples. For 
pure DNA this ratio should be greater than 1.8 and for pure RNA greater than 2.0. 
2.2.7 DNA digestion 
Plasmids and PCR products were digested using FastDigest restriction enzymes 
(Thermo Scientific, Waltham) at 37 °C. The amount of enzyme and the time of incubation 
were adjusted to the amount of DNA to be digested. Digestion buffers were used 
according to the manufacturer‟s instructions. For analytical digestions, 0.5 to 2 µg DNA 
were used. Preparative digestions for cloning require a higher amount of DNA, 5 to 6 µg. 
Also, all preparative digestions providing the plasmid backbone in subsequent cloning 
reactions were treated with 1 U of phosphatase (rAPid Alkaline Phosphatase, Roche, 
Basel, Switzerland) for the last 10 min of the digestion reaction to remove 5‟-phosphate 
groups preventing a re-ligation of the plasmid in the ligation reactions. Digested products 
were column-purified or separated by agarose gel electrophoresis and purified. 
2.2.8 Ligation and transformation of bacteria 
The desired insert and the dephosphorylated plasmid backbone were ligated using 
the T4 DNA ligase and a buffer allowing rapid ligation (Rapid DNA Ligation kit, Thermo 
Scientific). In a 10 µl reaction, 35 to 50 ng of plasmid were used with a three to four-fold 
molar excess of insert. As a control a ligation reaction without insert was prepared in 
parallel. Both were incubated at room temperature for 10 min. After incubation the ligation 
reaction was gently mixed with 50 - 100 µl of chemically competent bacteria that were 
thawed on ice. After 20 min incubation on ice, the bacteria were heat shocked at 42 °C for 
45 sec followed by addition of 250 µl of LB medium (2.1.5) and incubation at 37 °C for 
45 min. The bacteria suspensions were plated on agar plates containing ampicillin at 
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100 µg/ml as selective marker. The agar plates were incubated overnight at 37 °C. The 
next day, the number of colonies on the ligation plate was compared to that of the control 
plate allowing an estimation of the success rate. 
2.2.9 Preparation of plasmid DNA 
Individual bacterial colonies were picked and transferred to a liquid culture of 4 ml 
LB medium containing ampicillin (100 µg/ml). The cultures were incubated at 37 °C 
overnight while shaking at 150 rpm. Plasmid DNA was purified using the QIAprep 
Miniprep Kit (Qiagen, Hilden) according to the manufacturer‟s instructions. Taking 
advantage of the modified alkaline lyses by Birnboim and Doly (Birnboim and Doly, 1979), 
bacteria were lysed followed by a silica-based column purification of the plasmid DNA. 
The eluted DNA was sequenced at LCG genomics (Berlin) to validate the sequence of the 
new plasmid. 
2.2.10 Lentiviral vectors 
 Genetic manipulations of cells were obtained with lentiviral particles derived from the 
human immunodeficiency virus 1 (HIV-1). Such particles are able to transduce dividing 
and non-dividing cells. In this study, a second generation packaging system was used to 
produce them. It consists of a packaging plasmid, an envelope plasmid and the transfer 
plasmid encoding the particle‟s genome including the transgene and an antibiotic 
resistance gene or a fluorescence reporter gene. Upon transduction the transgene RNA 
genome is reverse transcribed and integrated into the cells‟ genome leading to a stable 
expression. I used transfer plasmids encoding for the knockdown of mRNAs and the 
ectopic expression of protein-coding sequences. For antibiotic resistance blasticidin, 
puromycin or hygromycin were employed. As fluorescence reporter genes I used Venus 
(Nagai et al., 2002), DsRed2 (Strack et al., 2008), mTurquoise2 (Goedhart et al., 2012) 
and mTagBFP (Subach et al., 2011). 
2.2.10.1 Production of lentiviral particles  
Lentiviral particles were produced in HEK 293T cells. In order to reach a 50 - 80 % 
confluency 6x106 cells were plated in 10 cm culture dishes 16 - 20 h prior to transfection. 
Each transfection was performed with 5 µg of the desired transfer plasmid, 1.8 µg of the 
envelope plasmid (pMD2G) and 5 µg of the packaging plasmid (pCMV-dR8.2). The 
plasmids were mixed into 600 µl of DMEM and 35 µl of transfection reagent were added 
(TransIT-LT1, Mirus Bio LLC, Madison, WI, USA). After 20 - 30 min of incubation at room 
temperature the mixture was spread evenly on the 293T cells. The supernatant was 
exchanged with fresh medium (DMEM, 10 % FBS) 24 h later. At 48 h, 60 h and 72 h post 
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transfection the supernatant containing lentiviral particles was collected and stored at 4 °C 
upon addition of HEPES-buffer (40 mM) to stabilize the pH (7.0). All supernatants were 
filtered after collection to remove cellular debris (0.2 µm Minisart, Sartorius AG, 
Göttingen). The filtered supernatant was aliquoted and stored at -80 °C. If required, e.g. 
for transduction of primary cells, it was concentrated by ultracentrifugation (4 °C, 
100000 g, 90 min) before storage. 
2.2.10.2 Transduction with lentiviral particles 
All cells were spin-transduced at 25 °C, 1000 g for 90 min in presence of polybrene 
(4 µg/ml hexadimethine bromide, Sigma Aldrich, St. Louis, MO, USA). Subsequently, cells 
were washed and provided with fresh medium. The amount of cells to be transduced 
determined the volume of supernatant containing lentiviral particles and the plate size. A 
standard cell line transduction was done with 0.8x106 cells in 1000 µl of the un-
concentrated lentiviral-containing supernatant in a 12-well plate. After transduction the 
washed cells were transferred to a 6-well plate and supplied with fresh medium. If smaller 
or larger amounts of cells were transduced, volumes were adapted accordingly. 24 h after 
transduction the respective selection reagent was added (puromycin, blasticidin or 
hygromycin). Untransduced control cells were used to determine completion of the 
selection. 
2.2.10.3 Determination of the efficiency of lentiviral particles 
 The efficiency of lentiviral particles was tested by a spin-transduction of 0.5x106 
K562 cells with 1/10 of the particle-containing supernatant that was used for a standard 
cell line transduction. As a control, pooled virus stocks with known efficiency were used 
for transduction in parallel. 2/3 of the cells were harvested after 48 h and genomic DNA 
was purified using the QIAmp DNA Mini Kit according to the manufacturer‟s instructions. 
Integration of the viral DNA into the genomic DNA was tested by quantitative PCR 
(qPCR). In addition, if the transfer plasmid encoded for a reporter fluorochrome, the 
remaining K562 were analyzed by flow cytometry. The expression level and the 
fluorescence intensity were used to predict the quality and the transduction rate of the 
particle-containing supernatant. 
2.2.11 RNA extraction, cDNA synthesis and qPCR 
RNA was extracted from TRIzol (Life Technologies, Carlsbad, CA, USA) according 
to the manufacturer‟s instructions. This procedure allows for a sequential isolation of RNA, 
DNA and proteins form the same sample and was first described by Chomczynski and 
Sacchi (Chomczynski and Sacchi, 1987). The TRIzol reagent is a monophasic solution 
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containing phenol and guanidine isothiocyanate. It dissolves all cell components during 
homogenization of the sample while maintaining the integrity of RNA due to RNAse 
inhibition. Upon addition of chloroform a phase separation is induced and the RNA can be 
precipitated from the aqueous phase with isopropanol. At least 200 ng of isolated RNA 
were used for cDNA synthesis with the QuantiTect Reverse Transcription Kit (Qiagen, 
Hilden). After elimination of potential traces of contaminating genomic DNA, the reverse 
transcription was performed using a mixture of Quantiscript reverse transcriptase (RT), 
Quantiscript RT buffer and RT primer mix. The reaction was performed according to the 
manufacturer‟s instructions. The cDNA was analyzed for gene expression with 
quantitative PCR (qPCR). A SYBR Green based assay was performed in triplicates on a 
CFX96 Real Time System (Bio-Rad Laboratories Inc., Hercules, CA, USA). Upon binding 
of double-stranded DNA, SYBR green fluoresces. The fluorescence intensity is measured 
after each PCR cycle and can be used to quantitate the amount of input DNA. Each 
reaction was prepared with 0.03 U AmpliTaqGold DNA Polymerase (LifeTechnologies, 
Carlsbad, CA, USA), 0.25 µM sequence-specific forward and reverse primer (see 
appendix) and 1x master mix containing SYBR green. Quantitative data were calculated 
with Ct-values from each reaction using mean primer pair efficiency. Data were 
normalized to at least two housekeeping genes, namely Vps39 and Ubqln1. 
2.2.12 Monitoring cell growth 
Cell growth was monitored using the CellTiter-Glo luminescent cell viability assay 
(Promega, Fitchburg, WI, USA). This assay quantifies the amount of ATP released from 
lysed cells by the oxidation of luciferin in presence of O2, Mg
2+ and ATP. Catalyzed by the 
Ultra-Glo recombinant luciferase, the oxidation results in oxyluciferin and thus in a stable 
luminescent signal that is proportional to the amount of viable cells. For growth monitoring 
of a standard cell line, 250,000 cells were plated in 2.5 ml medium in a 12-well plate. At 
each time point, 50 µl of each cell population plus 5 µl HEPES buffer (1 M) were 
thoroughly re-suspended with 100 µl of CellTiter-Glo Reagent. All cell populations were 
measured in triplicates in an opaque 96-well microplate suitable for luminescence 
measurement. The plate was incubated for 10 min at room temperature and luminescence 
was measured on the GloMax-Multi Detection System with 1 sec integration time in a 
predefined CellTiter-Glo protocol (Promega, Fitchburg, WI, USA). Growth was monitored 
every second day. All values of an individual cell suspension were normalized to its 
starting value. After the measurements, all cells were supplied with fresh medium 
including replacement of the medium taken for each measurement.  
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2.2.13 Cell culture 
2.2.13.1 Cell lines 
HEK 293T, a human embryonic kidney cell line used for production of lentiviral 
particles, were cultured in DMEM (DMEM high glucose, Life Technologies, Carlsbad, CA, 
USA) supplemented with 10 % heat-inactivated fetal bovine serum (FBS Gold, Biochrome, 
Berlin). Cells were trypsinized (1x Trypsin-EDTA solution) every second to third day and 
replated at a 1:3 to 1:5 dilution. K562 cells and OCI-AML2 cells, both human leukemic cell 
lines, were cultured in RPMI 1640 with L-glutamine (Life Technologies, Carlsbad, CA, 
USA) supplemented with 10 % FBS. For maintenance of 32D cells, a murine 
hematopoietic cell line, the same culture conditions were applied but in addition the media 
was supplemented with 5 ng/ml IL-3 (PeproTech, Hamburg).  
EML cells, a murine multipotent hematopoietic progenitor cell line (Tsai et al., 1994) 
were cultured in IMDM (BioWhittaker‟s IMDM with HEPES (25 mM), without l-glutamine, 
Lonza, Basel, Switzerland) supplemented with 20 % heat-inactivated horse serum (Sigma 
Aldrich, St. Louis, MO, USA), 10 % SCF-conditioned medium from the BHK/MKL cell line 
(see below), 2 mM L-glutamine and 100 U/ml Pen/Strep. For selection after transduction, 
the EML medium was supplemented with 8 µg/ml blasticidin (AppliChem, Darmstadt), 
1,5 µg/ml puromycin (SigmaAldrich, St. Louis, MO, USA) or 500 µg/ml hygromycin B (Life 
Technologies, Carlsbad, CA, USA). BHK/MKL cells (provided from S. Tsai, Utah) were 
cultured in DMEM supplemented with 10 % FBS. For passaging cells were trypsinized 
and replated at a 1:3 to 1:5 dilution.  
All sera were heat-inactivated prior to use. All suspension cell lines were passaged 
every second or third day.  
2.2.13.2 BHK/MKL stem cell factor conditioned medium 
The BHK/MKL cells are genetically modified to express the secretory form of rat Scf. Their 
conditioned medium provides the stem cell factor for the EML cell line. In order to produce 
a conditioned medium of high quality, the cells have to reach 60 - 80 % confluency. 16 -
 20 h prior to medium conditioning, 7x106 cells were plated in a T75 flask in 25 ml DMEM 
supplemented with 10 % heat-inactivated FBS. As the desired confluency was reached, 
medium was replaced by 50 ml fresh DMEM supplemented with 10 % heat-inactivated 
FBS. The conditioned 50 ml of medium were collected after 48 h, and were replaced by 
additional 60 ml of fresh medium. Again 48 h later, the conditioned medium was collected. 
All collected media were pooled, centrifuged (300 g, 5 min, room temperature), filtered 
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(0.2 µm Minisart, Sartorius AG, Göttingen) and stored in aliquots at  
-20 °C.  
2.2.13.3 Murine hematopoietic stem and progenitor cells 
Murine hematopoietic stem and progenitor cells were cultured in X-Vivo medium (X-
Vivo 15 without Gentamicin and Phenol Red, Lonza, Basel, Switzerland) supplemented 
with 10 % FBS, 2 mM L-glutamine, 100 U/ml Pen/Strep, 10 ng/ml mFlt3 ligand, 10 ng/ml 
mTpo and 20 ng/ml mScf. Cells were passaged every second day. For selection after 
transduction, the media was supplemented with 6 µg/ml blasticidin (AppliChem, 
Darmstadt), 1,5 µg/ml puromycin (SigmaAldrich, St. Louis, MO, USA) or 200 µg/ml 
hygromycin B (Life Technologies, Carlsbad, CA, USA). For the induction of tetracycline-
regulated gene expression the medium was supplemented with titrated amounts of 
doxycycline (Sigma Aldrich, St. Louis, MO, USA).  
2.2.14 Cytospins  
150,000 cells were washed in 1 ml MACS buffer three times. For the spin funnel 
application, the cells were resuspended in 150 µl of MACS buffer and centrifuged on 
microscope slides (2 min, 800 rpm, Shandon Centrifuge Cytospin II). The resulting 
cytospins were air-dried for 30 min. Staining was performed with May-Grünwald-Giemsa 
solution for 20 min in 1x Giemsa (Sigma Aldrich, St. Louis, MO, USA) followed by a 2 sec 
distilled water wash, a 2 min May-Grünwald (Sigma Aldrich, St. Louis, MO, USA) solution 
incubation followed by a 1 sec distilled water wash step. Dried slides were mounted with 
coverslips (Roth, Karlsruhe) using Eukitt quick-hardening mounting medium (Fluka 
Analytical, St. Gallen, Switzerland). 
2.2.15 Statistics 
All graphs and statistics were obtained with GraphPad Prism (Graph Pad Software, 
San Diego, CA, USA; version 5.04 for Windows). Flow cytometry data was analyzed using 
FlowJo (Tree Star Inc., Ashland, OR, USA). All figures were prepared using Microsoft 
PowerPoint. Geneious (Biomatters, Auckland, New Zealand) was used for plasmid and 
primer design as well as determination of restriction sites. 
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3. Results 
3.1 Establishment of a cell cycle-readout 
The most precise gene expression profiling including a cell cycle phase-based 
resolution would ask for an undisturbed separation of cells according to their cell cycle 
phase. Classically, an enrichment of cells in a certain phase is achieved by chemical 
synchronization or, less common, by physical separation. Chemical synchronization is 
accomplished by a block of metabolic reactions leading to an arrest of all cells in the same 
cell cycle phase; upon release these cells undergo a synchronized division. Such an 
arrest can be provoked either by nutrition deprivation (e.g. serum starvation) or by 
inhibition of DNA synthesis and microtubule activity (e.g. aphidicolin, thymidine, 
nocodazole, etc.). Unfortunately, both methods disturb essential signaling pathways. 
Physical separation, for example mitotic shake off or centrifugal elutriation, requires 
special equipment and a large number of cells to obtain enough synchronized cells for 
further analysis (Davis et al., 2001). Thus, the analysis of cell cycle-dependent gene 
expression in primary murine hematopoietic stem and progenitor cells precludes classical 
cell cycle synchronization. In particular, an undisturbed cell cycle progression would allow 
for a highly accurate gene expression analysis of Mybl2, an essential cell cycle regulatory 
gene. I aimed to test whether the fluorescent ubiquitination-based cell cycle indicator 
(Fucci) technique (1.4) (Sakaue-Sawano et al., 2008), specifically the improved version 
Fucci2 (Sakaue-Sawano et al., 2011), could be used for an accurate separation of cell 
cycle phases in murine HSPCs. To date, the Fucci technique had not been used for 
analysis and separation of hematopoietic cell lines or cultured murine hematopoietic stem 
and progenitor cells.  
3.1.1 Vector design and cloning 
I implemented the Fucci2 technique (Sakaue-Sawano et al., 2011) with certain 
modifications. First, I replaced the fluorochrome mCherry by the tetrameric DsRed-
Express2 (RFP) (Strack et al., 2008)), or alternatively mTurquoise2 (Tq) (Goedhart et al., 
2012)) to enable measurements on flow cytometers not equipped with a 561 nm yellow-
green laser. Second, instead of the Fucci2 ill-defined linker sequence that was designed 
to facilitate cloning steps, I introduced a defined glycine linker to fuse the fluorochrome 
protein to the cell cycle phase regulated protein domain. The glycine residues offer a high 
flexibility between the two protein domains. Further, I aimed to develop a single vector 
encoding both cell cycle indicators. This would facilitate the handling of vector 
transduction as well as the selection for transduced cells. Aiming to work with 
hematopoietic cells, I introduced the spleen focus-forming virus (SFFV) promoter to drive 
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expression of one of the fused proteins as it is one of the most potent promoters to drive 
gene expression in murine hematopoietic cells (Baum et al., 1995; Eckert et al., 1996). 
The other fusion protein was set up to be expressed under the control of the human 
phosphoglycerate kinase (hPGK) promoter.  
To generate the vectors needed to implement the Fucci2 technique, I first PCR-
amplified the RFP, the Tq and the Venus DNA sequences. In order to amplify the cell 
cycle gene-encoding DNA sequences and to introduce the glycine linker, I designed the 
forward primers for the CDT1(30/120) and the GMNN(1/110) DNA fragments with an overhang 
encoding the glycine sequence and part of the sequence encoding the fluorochrome to be 
linked. The cell cycle gene-encoding DNA sequences were then PCR-amplified. In a 
subsequent fusion PCR (2.2.3.1), the fluorochrome-encoding sequences were fused to 
the cell cycle gene-encoding sequences. Specifically, the amplified RFP- and Tq-encoding 
DNA sequences were fused to the amplified CDT1(30/120) DNA fragment and the Venus 
DNA sequence was fused to the amplified GMNN(1/110) DNA fragment. For cloning, I 
digested the fused PCR products (e.g. the Venus-GMNN(1/110) PCR product with the 
restriction enzymes BamHI and KpnI) before purification and ligation into a pRRL open 
vector backbone. The RFP-CDT1(30/120) and the Tq-CDT1(30/120) expression were each set 
up under the control of the SFFV promoter and the Venus-GMNN(1/110) expression was to 
be driven by the hPGK promoter. In total, I produced five plasmids, two encoding both, the 
CDT1(30/120) and the GMNN(1/110) cell cycle indicator fusion proteins (Figure 8, pVG7-RFPC, 
pVG7-TqC), and three plasmids encoding only one of the cell cycle indicator proteins 
(Figure 8, pVG, pRRL7-TqC, pRRL7-RFPC).  
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Figure 8: Modified Fucci vectors. Schematic outline of the expression cassettes of the modified 
Fucci vectors used in this study. Open boxes in dark green represent the promoter sequences, 
colored boxes represent the indicated fluorochrome linked to the cell cycle indicator fragment by a 
glycine linker (*).  
3.1.2 Testing the modified Fucci vectors 
I tested the Fucci vectors (Figure 8) by lentiviral vector transduction of the human 
leukemia cell line OCI-AML2. The transduced cells were analyzed for expression of the 
integrated vector cassette by flow cytometry. First, I established the flow cytometry 
protocol including the compensation using the vectors encoding only one fusion protein 
(single color). Prior to every analysis, a “live gate” determined by the forward scatter 
(FSC) and side scatter (SSC) parameters was defined to ensure exclusion of cellular 
debris for analysis (e.g. Figure 9 A, P1). I analyzed the cells for the expression of the cell 
cycle indicators and used fluorescence-activated cell sorting (FACS) to select for cells 
stably expressing the Fucci vector cassette. After expansion of the sorted cells, I tested 
the cell cycle-dependent expression of the cell cycle indicators by sorting cells according 
to the level of their fluorescence intensity. The sorted cells were re-analyzed using 
propidium iodide staining (PI staining) to confirm the anticipated cell cycle phase by DNA 
content analysis. The PI-based re-analysis was also performed by flow cytometry 
excluding debris, cell doublets and clusters (Figure 9 C) before the analysis of the PI 
fluorescence intensity, i.e. cell cycle profile.  
3.1.2.1 Single vector strategy 
First, I tested whether using a single vector encoding for both cell cycle indicator 
proteins would allow for the separation of cells according to specific cell cycle phases. I 
transduced one set of OCI-AML2 cells with the vector encoding for RFP-CDT1(30/120) and 
pVG7-RFPC RFP    CDT1 mVenus    GMNN 
pVG 
pRRL7-TqC mTq CDT1 SFFV 
pRRL7-RFPC 
SFFV * 
* Glycine linker 
hPGK 
mVenus     GMNN * hPGK 
RFP    CDT1 SFFV 
pVG7-TqC mTq hPGK CDT1 mVenus    GMNN SFFV * 
* 
* 
* 
* 
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Venus-GMNN(1/110) expression (Figure 8, pVG7-RFPC) and another set of cells with the 
vector encoding for Tq-CDT1(30/120) and Venus-GMNN(1/110) expression (Figure 8, pVG7-
TqC). 48 h post transduction, I analyzed the cells expressing RFP-CDT1(30/120) and Venus-
GMNN(1/110) for RFP and Venus expression by flow cytometry (Figure 9). A large amount 
of cells was neither positive for RFP nor for Venus expression (RFPneg/Venusneg: 45 %) 
comprising the untransduced cells. To select only those cells that stably expressed the 
cell cycle indicators, I sorted all cells that were either RFPpos, Venuspos or both using a 
NOT RFPneg/Venusneg gate (Figure 9 B). After expansion of the sorted cells stably 
expressing RFP-CDT1(30/120) and Venus-GMNN(1/110), they were analyzed a second time by 
flow cytometry (Figure 9 E). Surprisingly, again, a large fraction of RFPneg/Venusneg cells 
(25 %) appeared suggesting that the expression of the integrated vector cassette might 
not lead to sufficient expression levels of the fusion proteins in these cells. As a control for 
the following PI-based analysis, I chose to sort cells defined by the “live gate” (Figure 9 A, 
P1). Cells sorted for this gate have the advantage of representing a random sample of all 
transduced cells undergoing the same treatment, including FACS. The PI-based re-
analysis of these control cells showed a regular cell cycle profile (Figure 9 D) when 
compared to non-modified OCI-AML2 cells, demonstrating that the expression of the 
fusion proteins did not disturb cell cycle progression (data not shown). Next, I tested the 
cell cycle-dependency of the fusion protein expression by sorting different cells positive for 
at least one cell cycle indicator. I sorted RFPpos/Venusneg cells (Figure 9 E) anticipating 
them to be in the G1 phase of the cell cycle when analyzed by PI-staining. In addition, I 
sorted RFPpos/Venuspos cells (Figure 9 E) anticipating these cells to be enriched in the S 
phase when analyzed by PI-staining. However, while PI-based re-analysis showed that as 
expected RFPpos/Venusneg cells were exclusively in the G1 phase, the double-positive cells 
contained cells in every phase of the cell cycle (Figure 9 E). In theory, only S phase cells 
should express both cell cycle indicators simultaneously (RFPpos/Venuspos), while cells in 
the G1 phase should be exclusively RFPpos/Venusneg and cells in the G2 phase exclusively 
RFPneg/Venuspos. This lead to the conclusion, that RFPpos/Venuspos cells that were not in 
the S phase when analyzed by PI-staining were “contaminants” suggesting that either the 
degradation of RFP-CDT1(30/120) or Venus-GMNN(1/110) did not work properly in the 
transduced cells. Thus the PI-based re-analysis demonstrated that lentiviral transduction 
of OCI-AML2 cells with a single vector encoding for RFP-CDT1(30/120) and Venus-
GMNN(1/110) did not yield an optimal enrichment of S phase cells. Hence, one vector 
encoding for the expression of RFP-CDT1(30/120) and Venus-GMNN(1/110) did not allow for a 
successful cell cycle phase separation. The vector encoding for Tq-CDT1(30/120) and 
Venus-GMNN(1/110) – pVG-TqC – was tested in the same way as described for the vector 
encoding for RFP-CDT1(30/120) and Venus-GMNN(1/110) expression. However, the OCI-
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AML2 cells showed neither Tq expression nor double-positive cells, only a weak Venus 
expression was measurable by flow cytometry (data not shown). This observation could 
be explained by the fact that both fluorochromes originate from GFP (Goedhart et al., 
2012; Nagai et al., 2002). When Tq and Venus are encoded in the same vector, due to 
their high sequence homology, there is a tendency of recombination during reverse 
transcription in the transduction process, mostly resulting in expression of only one 
fluorescent protein (Aoki et al., 2012).  
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Figure 9: The “single vector strategy” did not lead to a successful cell cycle phase 
separation of OCI-AML2 cells. (A) Gate used to exclude cellular debris; “live gate” (P1). (B) 
Analysis of RFP-CDT1(30/120) and Venus-GMNN(1/110) expression in OCI-AML2 cells, all cells not 
RFP
neg
/Venus
neg
 were sorted to select for the transduced cells. (C) Gate to exclude cell doublets for 
the cell cycle analysis of PI-stained cells. (D) PI-based re-analysis of the control, i.e. cells sorted for 
the “live gate” (P1, A) (E) Left: Analysis for RFP-CDT1(30/120) and Venus-GMNN(1/110) expression of 
the cells sorted in (B) and the sort gates for RFP
pos
/Venus
neg
 and RFP
pos
/Venus
pos
 cells; right: PI-
based re-analysis of the RFP
pos
/Venus
neg
 and RFP
pos
/Venus
pos
 cells. 
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3.1.2.2 Dual vector strategy 
As the single vector encoding both cell cycle indicator proteins did not lead to a 
complete cell cycle phase separation, I decided to use separate vectors each encoding 
only one cell cycle indicator as performed in the initial study (Sakaue-Sawano et al., 
2008). Thus, I tested whether an appropriate cell cycle phase separation could be 
achieved in OCI-AML2 cells upon sequential transduction with two vectors. OCI-AML2 
cells were separately transduced with the vectors encoding for RFP-CDT1(30/120) and Tq-
CDT1(30/120) expression (Figure 8, pRRL7-RFPC, pRRL7-TqC). 48 h post transduction, I 
analyzed the cells for RFP and Tq expression by flow cytometry (Figure 10). Interestingly, 
the transduced cells showed a broad range of RFP and Tq fluorescence intensity (Figure 
10), especially when compared to the fluorescence intensity measured testing the single 
vector strategy (Figure 9). For the selection of cells stably expressing the cell cycle 
indicators, I sorted the RFPpos and Tqpos cells. To reveal possible differences between 
cells having a high or low expression level of RFP and Tq, I sorted cells showing a high 
fluorescence intensity (Figure 10; A: RFPhigh; B: Tqhigh) and cells showing a low 
fluorescence intensity (Figure 10; A: RFPlow; B: Tqlow). 
 
Figure 10: Flow cytometry analysis of OCI-AML2 cells expressing RFP-CDT1(30/120) or Tq-
CDT1(30/120) showed a broad range of fluorescence intensity. (A) OCI-AML2 cells analyzed for 
RFP-CDT1(30/120) expression and the gates for sorting of RFP
high
 and RFP
low
 cells. (B) OCI-AML2 
cells analyzed for Tq-CDT1(30/120) expression and the gates for sorting Tq
high
 and Tq
low 
cells. 
Surprisingly, the RFPhigh and Tqhigh cells died within 48 h of further cultivation 
suggesting that high-level expression of the CDT1(30/120) fusion protein might not be 
tolerated by the cells. The cells with lower fluorescence intensity of the CDT1(30/120) fusion 
proteins, OCI-AML2 RFPlow and OCI-AML2 Tqlow, kept proliferating and could be 
transduced with the pVG vector (Figure 8) encoding for the expression of the Venus-
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GMNN(1/110) fusion protein. Subsequently, the cells were sorted for the Venus
pos cells using 
flow cytometry (Figure 11, A and B).  
 
Figure 11: Flow cytometry analysis of OCI-AML2 RFP
low
 and Tq
low
 cells transduced with the 
vector encoding for Venus-GMNN(1/110) expression. (A) The gate for sorting Venus
pos
 cells of the 
OCI-AML2 RFP
low
 cells. (B) The gate for sorting Venus
pos
 cells of the OCI-AML2 Tq
low 
cells. 
The cells transduced and sorted twice, stably expressing both cell cycle indicators 
were expanded in culture to test whether their fluorescence label would reflect the 
indicated cell cycle phase. 
First, I analyzed the OCI-AML2 cells expressing RFP-CDT1(30/120) and Venus-
GMNN(1/110) by flow cytometry. Again many cells were double-negative (40 %; Figure 12, A 
and B), similar to the results of the single vector strategy (3.1.2.1). As I had selected the 
transduced cells by FACS (Figure 10; Figure 11), the remaining double-negative cells 
indicated that the introduced vector cassettes might not lead to sufficient expression levels 
of the fusion proteins. In addition, the flow cytometric analysis showed that more cells 
were RFPneg/Venuspos (28 %), representing the cells in the G2 phase, than 
RFPpos/Venusneg (12 %), representing the cells in the G1 phase of the cell cycle (Figure 
12, A and B, left panel). In contrast, PI-based re-analysis of these cells sorted for the “live 
gate” as a control showed more cells in the G1 phase than the G2 phase (Figure 12 B, 
control). This finding suggested that the expression of the cell cycle indicators did not 
label all cells according to their cell cycle phase. To test whether some cells were correctly 
labeled showing a cell cycle-dependent expression of the fusion proteins, I sorted different 
cell populations according to their fluorescence intensity. I sorted RFPpos/Venusneg cells 
(Figure 12 A, P2) and two Venuspos cell populations, one showing a high RFP expression 
(Figure 12 A, P3), the other showing a low RFP expression (Figure 12 A, P4). As 
Results 
44 
 
anticipated the RFPpos/Venusneg (Figure 12 A, P2) cells were exclusively in the G1 phase 
of the cell cycle when re-analyzed by PI-staining (Figure 12 A, P2). Re-analyzing the 
Venuspos/RFPhigh (Figure 12 A, P3) and Venuspos/RFPlow (Figure 12 A, P4) cells, I 
expected both populations to be enriched in the S phase. As the RFP-CDT1(30/120) fusion 
protein is degraded during the onset of S phase, I anticipated to see an increasing amount 
of cells in the late S/G2 phase upon reduction in RFP fluorescence intensity. Surprisingly, 
both cell populations had almost the same cell cycle profile analyzed by PI-staining 
(FigureFigure 12 A, P3 and P4). Moreover, they both contained cells in all phases of the 
cell cycle. However, as RFP-CDT1(30/120) is degraded during the S phase and Venus-
GMNN(1/110) quickly disappears after M phase, double positive cells (RFP
pos/Venuspos) 
should be exclusively in the S phase. Thus, the analysis of the cells expressing RFP-
CDT1(30/120) and Venus-GMNN(1/110) did not allow for a strict correlation between 
fluorescence and cell cycle phase. In contrast, the results of the experiment suggested 
that most cells either express RFP-CDT1(30/120) constantly or silenced its expression. To 
clarify this, I sorted RFPpos and RFPneg cells (Figure 12 B, upper left) expecting to see two 
identical cell cycle profiles by PI-based re-analysis. Indeed, both sorted cell populations 
showed an almost regular and identical cell cycle profile (Figure 12 B, bottom) as revealed 
by comparison to the PI-based re-analysis of the control consisting of cells sorted for the 
“live gate” (Figure 12 B, control). These results demonstrated that some cells were RFPpos 
throughout the whole cell cycle, while others silenced the RFP-CDT1(30/120) expression and 
thus stayed RFPneg in every cell cycle phase. Moreover, a selection in favor of the cells 
that silenced the RFP-CDT1(30/120) expression could explain the high amount of double-
negative cells representing the G1 phase cells with a silenced RFP-CDT1(30/120) 
expression opposite to the small amount of RFPpos/Venusneg cells representing the cells in 
the G1 phase that did not silence the RFP-CDT1(30/120) expression. Also, as the double-
negative cells probably silenced only the RFP-CDT1(30/120) expression, they might still 
express Venus-GMNN(1/110) in a cell cycle-dependent manner, thus, label the G2 phase 
cells correctly. This could explain the unusual ratio of RFPneg/Venuspos (G2 phase) to 
RFPpos/Venusneg (G1 phase) cells initially noticed (Figure 12, A and B).  
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Figure 12: Using two separate vectors did not lead to a successful cell cycle phase 
separation. (A) Sort gates P2, P3 and P4 used to test the cell cycle-dependence of the cell cycle 
indicators and the corresponding PI-based re-analysis. (B) Sort gates RFP
pos
 and RFP
neg
 (upper 
left panel), the corresponding PI-based re-analysis (bottom panel) and as a control the PI-based 
analysis of cells sorted for the “live gate” (control, upper right panel). 
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These data showed that the separation of the different cell cycle phases by flow 
cytometry through the expression of RFP-CDT1(30/120) and Venus-GMNN(1/110) introduced 
by sequential transduction of OCI-AML2 cells was not feasible. However, RFP being a 
tetrameric protein might have led to the problems I faced introducing RFP-CDT1(30/120) as 
the G1 cell cycle indicator. Thus, I decided to test whether the dual vector strategy would 
work using Tq, which is a monomeric protein. Again, the flow cytometry analysis of OCI-
AML2 cells expressing Tq-CDT1(30/120) and Venus-GMNN(1/110) showed a large number of 
Venusneg/Tqneg cells (30 %; e.g. Figure 13 A) although they had been previously enriched 
for cell stably expressing both vectors (Figure 10; Figure 11). Additionally, more cells were 
Venuspos/Tqneg (43 %) representing cells in the G2 phase compared to Tqpos/Venusneg cells 
(6 %) representing the G1 phase (e.g. Figure 13 A), consistent with the observation 
testing the dual vector strategy with RFP-CDT1(30/120) as the G1 phase indicator (Figure 
12, A and B). This finding already indicated that the dual vector strategy using Tq-
CDT1(30/120) might as well show an incorrect labeling of the cell cycle phases. To clarify 
this, I tested the cell cycle-dependence of the cell cycle indicator proteins by sorting five 
different cell populations. First, I sorted three cell populations similar to the ones I used for 
the analysis of the RFP-CDT1(30/120) and Venus-GMNN(1/110) expressing cells. Two 
Venuspos cell populations, one showing a high Tq expression (Figure 13 A, P2), the other 
showing a low Tq expression (Figure 13 A, P3). Similar to the analysis of RFP-CDT1(30/120) 
and Venus-GMNN(1/110) expressing cells, PI-based re-analysis of these two populations – 
Tqhigh/Venuspos and Tqlow/Venuspos – showed that both had almost the same cell cycle 
profile (Figure 13 A) and were not only enrichment in the S phase, but also in the G2 
phase (Figure 13 A). This indicated that, although the Tq-CDT1(30/120) should be degraded 
towards the end of the S phase of the cell cycle, some cells show a constant Tq 
expression. To confirm this, I sorted a third cell population containing all cells that were 
Tqpos (Figure 13 B) expecting to see a regular cell cycle profile instead of an enrichment of 
cells in the G1/S phase. Indeed, the PI-based re-analysis showed an almost regular cell 
cycle profile (Figure 13 B) similar to that of the RFPpos cells analyzed earlier (Figure 12 B). 
Again, this led to the conclusion that some cells stay Tqpos throughout the whole cell cycle, 
meaning the Tq-CDT1(30/120) is not degraded properly in the S phase.  
While the G1 phase cell cycle indicators – the CDT1(30/120) fusion proteins – were 
either not degraded in a cell cycle-specific manner or their expression was silenced, 
Venus-GMNN(1/110) appeared to be accumulated and degraded cell cycle-dependently. 
Thus, to test whether the change in Venus-GMNN(1/110) fluorescence intensity did correlate 
with the cell cycle progression and might be used to separate a cell population into 
different cell cycle phases, I sorted two additional cell populations: Venuslow/Tqneg cells 
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(Figure 13 C, P4) and Venushigh/Tqneg cells (Figure 13 C, P5). As Venus-GMNN(1/110) 
accumulates over S/G2 phase, I expected the Venus fluorescence intensity to increase 
towards the G2 phase of the cell cycle. Consequently, I expected that the Venuslow/Tqneg 
cell population (Figure 13 C, P4) would be enriched in the S phase and the Venushigh/Tqneg 
cell population (Figure 13 C, P5) in late S/G2 phase. Indeed, the PI-based re-analysis of 
the sorted cells confirmed these predictions (Figure 13 C). Although the analysis of the 
OCI-AML2 cells expressing Tq-CDT1(30/120) and Venus-GMNN(1/110) did not lead to a 
successful cell cycle phase separation, the results strongly indicated the possibility to use 
Venus-GMNN(1/110) as a single cell cycle indicator allowing for a very precise and 
unperturbed cell cycle phase separation.  
In summary, neither the dual vector strategy with RFP-CDT1(30/120) and Venus-
GMNN(1/110) nor with Tq-CDT1(30/120) and Venus-GMNN(1/110) led to the desired result of an 
accurate cell cycle phase separation by flow cytometry. Both CDT1(30/120) fusion proteins 
were either expressed throughout the whole cell cycle or had been silenced. However, the 
Venus-GMNN(1/110) fusion protein seemed to be accumulated and degraded in a cell cycle 
dependent manner as I could separate two cell cycle phases by Venus fluorescence 
intensity, only (Figure 13 C). Thus, I decided to focus on establishing a cell cycle-readout 
relying on the Venus-GMNN(1/110) expression as a single cell cycle indicator. 
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Figure 13: The expression of Tq-CDT1(30/120) and Venus-GMNN(1/110) in OCI-AML2 cells did not 
lead to a successful cell cycle phase separation but suggested that Venus-GMNN(1/110) could 
be useful as a single cell cycle phase indicator. (A) Sort gates P2 and P3 used to test the cell 
cycle dependent expression of Tq-CDT1(30/120) and Venus-GMNN(1/110) and the corresponding PI-
based re-analysis. (B) Sort gate Tq
pos
 and the corresponding PI-based re-analysis. (C) Sort gates 
P4 and P5 used to test the cell cycle-dependent expression of Venus-GMNN(1/110) and the 
corresponding PI-based re-analysis. 
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3.1.3 Venus-GMNN(1/110) as single cell cycle indicator 
As the Venus-GMNN(1/110) fusion protein degradation and accumulation within the 
cell cycle appeared to function properly, I proceeded in testing whether Venus-GMNN(1/110) 
as a single cell cycle indicator for the S/G2/M phase could be used to separate cells into 
all cell cycle phases. Aiming to work with murine HSPCs, I performed the experiments in 
murine hematopoietic cell lines, starting with 32D cells, a well-established murine cell line. 
I first transduced the cells with the vector encoding for the Venus-GMNN(1/110) expression 
only (Figure 8). The transduced cells were enriched by sorting the Venuspos cells and after 
further expansion sorted into different cell populations according to the Venus 
fluorescence intensity. After sorting, I analyzed the cell cycle phase of the sorted cells by 
PI-based re-analysis. I expected an increase in mVenus fluorescence intensity with 
progression of the cells towards the G2 phase. Thus, the Venusneg cells should be 
enriched in the G1 phase, the Venuslow cells in the S phase and the Venushigh cells in the 
G2 phase of the cell cycle.  
3.1.3.1 Venus-GMNN(1/110)-based cell cycle analysis in the 32D cell line 
I transduced 32D cells with the pVG vector (Figure 8) to test whether the expression 
of Venus-GMNN(1/110) could be used as a single cell cycle indicator in a simple murine 
hematopoietic cell line. After transduction, I selected the cells for the expression of Venus-
GMNN(1/110) by FACS. The analysis of an untransduced control of 32D cells (Figure 14 A) 
was used to set the correct gate for sorting the Venuspos cells (Figure 14 B).  
 
Figure 14: Flow cytometry analysis of 32D cells. (A) Untransduced 32D cells. (B) 32D cells 
expressing Venus-GMNN(1/110) and the sort gate for Venus
pos
 cells. 
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After further expansion, the sorted cells should stably express the Venus-
GMNN(1/110) fusion protein (32D VG). Next, they were sorted into subpopulations by flow 
cytometry aiming to test the cell cycle-dependency of the Venus-GMNN(1/110) expression. 
Gaiting on the “live gate” (Figure 15 A, P1), I sorted five cell populations with increasing 
Venus fluorescence intensity (Figure 15 B, P2-6). 
 
Figure 15: Flow cytometry sorting of 32D VG cells. (A) “Live gate” (P1). (B) Sort gates 
according to the Venus fluorescence intensity. 
As Venus-GMNN(1/110) accumulates over S/G2, the Venus fluorescence intensity 
should increase, as well. I expected Venusneg cells (Figure 15 B, P2) to be in the G1 
phase of the cell cycle. Thus, I anticipated the cells with the lowest Venus intensity (Figure 
15 B, P3) to be in the late G1/early S phase and the cells with the highest Venus intensity 
(Figure 15 B, P6) to be in the late S/G2 phase. Indeed, PI-based re-analysis of the sorted 
cells confirmed these expectations (Figure 16). The sorted Venusneg cell population 
(Figure 15 B, P2) showed a pure G1 phase peak (Figure 16, P2), while the cells sorted for 
increasing Venus fluorescence intensity (Figure 15 B, P3-6) each were enriched in a 
different cell cycle phase displaying a progress from the G1 to the G2 phase: the P3 cell 
population (Figure 15 B) was enriched in the late G1/S phase (Figure 16, P3), the P4 cell 
population (Figure 15 B) in the S phase (Figure 16, P4), the P5 cell population (Figure 
15 B) in the S/early G2 phase (Figure 16, P5) and the P6 cell population (Figure 15 B) in 
the late S/G2 phase (Figure 16, P6). Importantly, PI-based re-analysis of cells sorted for 
the “live gate” (Figure 15 A, P1) as a control showed a regular cell cycle profile (Figure 16, 
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P1) supporting that the Venus-GMNN(1/110) expression did not alter the typical distribution 
of cells in each cell cycle phase.  
 
Figure 16: PI-based re-analysis of the 32D VG cells sorted according to the Venus-
GMNN(1/110) fluorescence intensity revealed a distinct cell cycle phase separation. PI-based 
re-analysis of the cells sorted for the “live gate” and the gates sorted according to the Venus 
fluorescence intensity (Figure 15, A and B, P1-P6). 
In conclusion, Venus-GMNN(1/110), as a single cell cycle indicator, allowed for a very 
distinct cell cycle phase separation of the 32D VG cells. The sorted populations were 
enriched without perturbation of the cell cycle progression and thus, this experimental 
design promised the possibility of a highly accurate gene expression analysis at the cell 
cycle phase level.  
3.1.3.2 Venus-GMNN(1/110)-based cell cycle analysis in the EML cell line 
To confirm my findings, I tested the described setup using the EML cell line, as well. 
The EML cell line is a murine hematopoietic progenitor cell line immortalized by a 
retroviral vector encoding a dominant-negative version of the retinoic acid receptor (Tsai 
et al., 1994). This cell line has differentiation potential and, thus, is very close to primary 
murine HSPCs. I transduced the cells with the vector encoding for the Venus-GMNN(1/110) 
expression (Figure 8) and selected for the transduced cells by sorting the Venuspos cells 
(EML VG), as described before (3.1.3.1). After 48 h of further cultivation, I analyzed the 
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sorted EML VG cells a second time for their Venus-GMNN(1/110) expression using flow 
cytometry (Figure 17, A and B). 
 
Figure 17: Flow cytometry sorting of EML VG cells. (A) “Live gate” (P1). (B) Sort gates 
according to the Venus fluorescence intensity. 
To show that neither expression of Venus-GMNN(1/110) nor the FACS would alter the 
cell cycle profile of the EML cells, I used the following three controls: untransduced and 
unsorted EML cells, as a non-treated control, unsorted EML VG cells and EML VG cells 
sorted for the “live gate” (Figure 17 A, P1). Indeed, the PI-based re-analysis showed that 
all of the three analyzed controls had an almost identical and regular cell cycle profile 
(Figure 18) underlining that the Venus-GMNN(1/110) vector expression allowed for an 
unperturbed cell cycle phase progression.  
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Figure 18: Comparison of the PI-based analysis of controls consisting of differentially 
treated EML cells underlined that expression of Venus-GMNN(1/110) did not alter the cell cycle 
progression. EML cells untransduced and unsorted, EML VG cells unsorted and EML VG cells 
sorted for the “live gate” were analyzed after PI-staining. 
I anticipated that PI-based re-analysis of the five cell populations I sorted according 
to their Venus fluorescence intensity (Figure 17 B, P2-P6) would show a similar cell cycle 
phase separation compared to those obtained with 32D VG cells. Indeed, as expected the 
Venusneg cells were enriched in the G1 phase (Figure 19, P2) while the cells with the 
highest Venus fluorescence intensity were enriched in the late S/G2 phase (Figure 19, 
P6). This analysis confirmed that the Venus fluorescence intensity can be used to 
separate the cell cycle phases. 
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Figure 19: PI-based re-analysis of the EML VG cells sorted according to the Venus-
GMNN(1/110) fluorescence intensity revealed a distinct cell cycle phase separation. Overlay of 
cell cycle profiles from EML control cells (Figure 18) and PI-based re-analysis of the gates sorted 
according to the Venus fluorescence intensity (Figure 17 B, P2-6). 
3.1.3.3 Expression of cell cycle marker genes in EML VG cells 
Next, to confirm that cells of each sorted cell cycle phase population indeed 
reflected their cell cycle stage by expression of specific marker genes, I performed gene 
expression analysis experiments for selected genes. I chose E2f transcription factor 1 
(E2f1) and cyclin E1 (Ccne1) as indicators for the G1/S phase, dihydrofolate reductase 
(Dhfr) as indicator for the S phase and forkhead box M1 (Foxm1) as indicator for the G2 
phase. As controls, I used EML VG cells, unsorted (Figure 20, control) or sorted for the 
“live gate” (Figure 17, P1; Figure 20, P1).  
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Figure 20: Gene expression in EML VG cells sorted according to the Venus-GMNN(1/110) 
fluorescence intensity showed known cell cycle phase distribution of the expression of the 
chosen cell cycle genes. QRT-PCR analysis was performed for known cell cycle genes in the 
EML VG cells sorted according to the Venus fluorescence intensity (Figure 17, P2-6;). Controls 
were EML VG cells unsorted (control) and sorted for the “live gate” (Figure 17, P1). Measurements 
were performed in triplicates. 
The QRT-PCR results confirmed the known cell cycle phase dependence of 
expression levels for the chosen cell cycle genes (Figure 20). For example, Dhfr, a typical 
S phase gene, had its highest expression level within the S phase cell population (Figure 
20). Also, the gene expression levels in the two controls did not show a significant 
difference compared to each other. This verified that the sorting of cells according to their 
cell cycle phase allowed for an accurate analysis of gene expression.  
Taken together, the results of the gene expression analysis and the PI-based 
analyses underlined the fact that the separation of the cell cycle phases using Venus-
GMNN(1/110) did not disturb the expression of known cell cycle genes or the progression of 
the cell cycle. Thus, the established method allowed for an unperturbed enrichment of 
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different cell cycle phases even in a cell line that is closely related to undifferentiated 
primary hematopoietic cells.  
3.2 Clonal dominance of HSPCs mediated by sub-haploinsufficient Mybl2 
expression levels 
3.2.1 Clonal expansion of HSPCs in vitro 
 Recently, MYBL2 has been identified as a sub-haploinsufficient tumor suppressor 
in MDS, inducing myelodysplastic tumor growth in a gene dosage dependent manner at 
an expression level of 30 - 50 % (Heinrichs et al., 2013). In the mentioned study, a 
competitive bone marrow transplantation assay in mice showed that primary murine bone 
marrow cells with sub-haploinsufficient expression levels of Mybl2 – mediated by RNA 
interference (RNAi) – became clonally dominant and the mice developed myeloid 
disorders. To date, it had not been tested whether a sub-haploinsufficient expression level 
of Mybl2 would also have a clonal advantage for murine lineage-negative (lin.-neg.) 
enriched bone marrow cells in vitro.  
 Prior to testing whether HSPCs with reduced Mybl2 expression level would expand 
in vitro, the knockdown efficiency of the specific Mybl2 shRNA used in the study 
mentioned above was tested in EML cells and freshly isolated murine HSPCs from wild-
type mice using QRT-PCR for Mybl2 expression analysis. A reduced Mybl2 expression 
level of 30 - 50 % was successfully reached after introduction of the constitutively 
expressed Mybl2 shRNA via lentiviral vector transduction (Figure 21).  
 
Figure 21: Knockdown verification in EML cells and HSPCs. The knockdown efficiency of the 
Mybl2 shRNA to a 30 - 50 % expression level of Mybl2 was successfully tested in vitro. Control 
cells were transduced with a lentiviral vector encoding an ill-defined shRNA (ctrl. shRNA). 
Measurements were performed in triplicates. 
 
Results 
57 
 
 In order to test the expansion of murine HSPCs in vitro upon an RNAi mediated 
Mybl2 knockdown to levels of 30 - 50 % (Mybl2 shRNA), I first isolated lin.-neg. enriched 
murine bone marrow cells from wild type mice. 24 h later, one part of the isolated cells 
was transduced with a lentiviral vector encoding the tested Mybl2 shRNA. To have 
different controls in this experiment, I transduced another part of the isolated cells with 
one of two lentiviral vectors each encoding an ill-defined shRNA (ctrl. shRNA1 and ctrl. 
shRNA2). Additionally, some cells were left as untransduced controls. All lentiviral vectors 
carried a red fluorescent protein sequence (DsRed-Express2/RFP) (Strack et al., 2008) to 
enable monitoring of the frequency of transduced cells by flow cytometry. 48 h post 
transduction, I first measured the RFP frequency in each of the three transduced cell 
cultures. Subsequently, I adjusted the frequency of RFP positive cells by addition of non-
transduced cells, in order to start monitoring cell growth and possible clonal dominance 
from the same level of transduced cells in each culture. 
 After the first week in culture, basically no difference in growth could be measured. 
However, during the course of the second week all control cell cultures lost their 
proliferative capacity, while cells with a reduced Mybl2 expression level kept expanding 
(Figure 22). This already indicated a proliferative advantage of cells, induced by reduced 
Mybl2 expression levels in vitro. 
 
Figure 22: Clonal dominance in vitro. Growth of murine lineage-negative enriched bone marrow 
cells either untransduced, transduced with a control shRNA (ctrl. shRNA 1 or 2) or a specific Mybl2 
shRNA encoding vector. Cell count was performed using a Neubauer counting chamber.  
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 In a weekly interval, I measured the RFP frequency of each transduced cell culture. 
While the RFP frequency, thus the frequency of transduced cells, was stable in the control 
cells, the RFP frequency in the cell culture with a low Mybl2 expression level increased 
significantly over time (Figure 23 A). This supported the idea that low expression levels of 
Mybl2 result in a proliferative and clonal advantage of HSPCs in vitro. In addition to 
monitoring the RFP frequency, I analyzed the immunophenotype of the cell cultures using 
a standard immunophenotyping panel for HSPCs to determine the amount of lin.-neg., 
thus immature, cells within each culture. I anticipated that, while cells with low Mybl2 
expression levels would stay rather immature over the monitored course of time, the 
control cells would differentiate. Indeed, while control cells were fully differentiated after 
two weeks, the cell culture with a reduced Mybl2 expression level kept increasing the 
amount of lineage negative cells over time reaching a frequency of almost 90 % after 30 
days in culture (Figure 23, B and C). Morphologic analysis of cytospins performed with the 
same cultures after about two weeks of proliferation supported these findings (data not 
shown).  
 This demonstrated that freshly isolated lin.-neg. enriched murine bone marrow cells 
proliferate and differentiate in cell culture within two weeks. In contrast, cells with a low 
Mybl2 expression level gain a self-renewal potential, show clonal dominance and a 
proliferative advantage. Over time, the amount of lin.-neg. cells driven by reduced 
expression levels of Mybl2 increased and an immature cell population could be observed. 
In summary, a Mybl2 knockdown to expression levels between 30 - 50 % led to 
immortalization of hematopoietic stem and progenitor cells in vitro. 
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Figure 23: Immunophenotype of cells with a low Mybl2 expression level in vitro. (A) RFP 
frequency of the cells transduced with a control shRNA (ctrl. shRNA 1 or 2) or a specific Mybl2 
shRNA encoding vector. (B) Frequency of lineage negative cells in cells transduced with a control 
shRNA (ctrl. shRNA 1 or 2) or a specific Mybl2 shRNA encoding vector. (C) Flow cytometry 
analysis of the cells transduced with the specific Mybl2 shRNA and one control shRNA at different 
time points post transduction. (d = days). Cells were stained with a lineage detection cocktail 
containing antibodies against epitopes of murine CD11b, Ly6-G/C, CD45R, CD5, Terr119, 7-4.  
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3.2.2 Establishment of an inducible ectopic Mybl2 expression  
 In order to address the question which genes are affected by the Mybl2 knockdown, 
I took advantage of a transgenic mouse line expressing a transcription factor with 
inducible transcriptional activity. This setup allowed reverting low levels of Mybl2, and 
possibly the proliferative phenotype seen in lin.-neg. enriched murine bone marrow cells in 
vitro (3.2.1). Meaning, re-expression of ectopic wild-type Mybl2 would ideally “rescue” the 
proliferative advantage and, consequently, stop cell growth.  
3.2.2.1 Tetracycline controlled transcription 
To control gene expression in an inducible and reversible manner, tetracycline 
controlled transcription has become very important for experimental setups. In this thesis, 
a transgenic mouse line (Rosa26 M2-rtTA, 2.1.8) expressing a reverse tetracycline-
controlled transactivator protein, M2-rtTA (Gossen and Bujard, 1992; Urlinger et al., 
2000), with inducible transcriptional activity, was used. All cells taken from these mice 
constitutively express a tetracycline-controlled transcription factor (rtTA) that is activated 
in presence of doxycycline. It binds to the TetOperator and activates transcription (Figure 
24) (Hochedlinger et al., 2005). In my experiments Mybl2 was introduced as the 
downstream target to be inducible upon doxycycline treatment.  
 
Figure 24: Tetracycline controlled gene transcription in cells from M2-rtTA mice 
(Hochedlinger et al., 2005). Upon addition of doxycycline (dox) the tetracycline responsive 
transcription factor is activated and binds to the TetOperator (TetO). Downstream target 
transcription of a coding DNA sequence (CDS) is then initiated. (Pmin = minimal pormotor). 
3.2.2.2 Vector design and experimental testing 
 In order to test the inducibility of ectopic Mybl2 expression using the tetracycline 
controlled gene transcription in cells from M2-rtTA mice, I designed a vector encoding for 
the inducible wild-type Mybl2 expression and, for selection purposes, a constitutive 
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blasticidin resistance (Figure 25 A, pT6B-Mybl2). A vector only encoding for the blasticidin 
resistance was used as a control (Figure 25 A, pLE11-Blast). To test for the inducibility of 
the ectopically introduced Mybl2, I decided to compare ectopic and endogenous Mybl2 
expression levels using QRT-PCR in cells either transduced with the inducible Mybl2 
expression vector or with the control vector, both in absence and presence of doxycycline. 
For the endogenous expression, I designed an oligonucleotide pair (primer pair) 
complementary to the 3‟UTR of Mybl2 as this part is exclusive to the endogenous Mybl2 
transcript. To measure expression levels of ectopic Mybl2 separately, I used a primer pair 
unique to the introduced lentiviral vector. The combined ectopic and endogenous Mybl2 
expression levels were measured using a regular Mybl2 CDS primer pair. 
 After 24 h of cultivation, freshly isolated lin.-neg. bone marrow cells form M2-rtTA 
mice were transduced either with the vector encoding for the inducible Mybl2 expression 
or the control vector. After blasticidin selection, I supplemented half of each cell culture 
with doxycycline (1 µg/ml) for 48 h. All four cell culture groups were analyzed by QRT-
PCR for endogenous, ectopic and the combined expression level of Mybl2 (Figure 25 B). I 
expected that endogenous Mybl2 expression would show a similar level in all analyzed 
cell cultures, while the ectopic and the combined Mybl2 expression levels would be 
increased only in the cells carrying the inducible Mybl2 cassette treated with doxycycline. 
Indeed, the analysis of the endogenous Mybl2 expression levels in cells with and without 
doxycycline treatment showed very similar expression levels (Figure 25 B, right panel). 
Thus, endogenous Mybl2 expression was not influenced by the induction of ectopic Mybl2 
expression. Looking at the ectopic Mybl2 expression levels of all analyzed cell cultures, 
only the cells carrying the inducible Mybl2 vector had a significantly higher expression of 
Mybl2 upon doxycycline treatment (Figure 25 B, left panel, pT6B+). Measuring the 
combined ectopic and endogenous Mybl2 expression, again cells with the inducible Mybl2 
expression showed an increased Mybl2 expression upon doxycycline treatment (Figure 
24 B, middle, pT6B+). However, the combined Mybl2 expression level was also slightly 
elevated in cells with inducible Mybl2 expression but in absence of doxycycline (Figure 
25 B, middle, pT6B-). This might indicate that in some cells Mybl2 was ectopically 
expressed independently from doxycycline treatment.  
 The experimental test showed that ectopic expression of Mybl2 did not alter 
endogenous Mybl2 expression, and an induction of ectopic Mybl2 was feasible upon 
doxycycline addition with a stable up-regulation of Mybl2 expression levels. 
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Figure 25: Test of the inducible system. (A) Vector design: pT6B-Mybl2 encoding for the 
inducible expression of Mybl2 and pLE11-Blast used as a control (B) Ectopic (left panel), 
endogenous (right panel) and the combined (middle) expression level of Mybl2 in lin.-neg. enriched 
murine bone marrow cells transduced with the inducible Mybl2 vector (pT6B) or the control vector 
(Blast), both either in absence (-) or presence (+) of doxycycline. Measurements were performed in 
triplicates. 
 
3.2.3 Re-expression of Mybl2 abrogates proliferation 
 In order to test whether re-expression of ectopic Mybl2 would abrogate the 
phenotype by reduced Mybl2 expression levels in lin.-neg. enriched bone marrow cells 
(3.2.1), I designed a vector encoding both, the constitutive Mybl2 knockdown and the 
inducible Mybl2 expression (Figure 26 A). For selectional purposes a blasticidin resistance 
was included. As a control vector, I used one only encoding the inducible Mybl2 
expression and a blasticidin resistance (Figure 26 B).  
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Figure 26: Vector design for inducible re-expression of wild-type Mybl2 in cells with reduced 
Mybl2 levels. (A) One vector encoding for the constitutive Mybl2 knockdown and the inducible 
Mybl2 expression, along with a constitutively expressed blasticidin resistance gene. (B) The control 
vector, only encoding for the inducible Mybl2 expression and the constitutively expressed 
blasticidin resistance gene.  
 To test whether ectopic expression of Mybl2 could “rescue” the growth phenotype 
induced by reduced Mybl2 expression levels, I set up an experiment recording growth of 
cells with low Mybl2 expression levels compared to cells with re-expressed Mybl2 using 
the inducible system (3.2.2). Again, 24 h after purification, I transduced lin.-neg. enriched 
bone marrow cells from M2-rtTA mice with the designed vectors, and blasticidin selection 
was performed. Yet again, cells with the constitutive Mybl2 knockdown and the inducible 
Mybl2 expression, as well as cells with the control vector, were cultured in presence and 
absence of doxycycline (1 µg/ml, 48 h). I anticipated that cells with a reduced Mybl2 
expression level would show a clear proliferative advantage compared to the controls and 
continue expansion over the monitored time period. Further, I hypothesized that the 
ectopic re-expression of Mybl2 upon doxycycline addition would abrogate this phenotype 
within a certain time. In contrast, I expected that the cells transduced with the control 
vector, as well in absence as in presence of doxycycline, would stop proliferating after 
about two weeks in culture. Indeed, while cells with a reduced Mybl2 expression level kept 
proliferating, the re-expression of ectopic Mybl2 could prevent this phenotype (Figure 
27 A, red and blue line). Also, both control cell cultures lost their proliferative capacity 
within two to three weeks of cultivation (Figure 27 A, dark and light green line). This result 
supported that the growth phenotype is caused by reduced Mybl2 expression levels, as it 
can be abrogated by re-expression of Mybl2. Of note, the ectopic expression of Mybl2 did 
not have an advantage for primary murine HSPCs in vitro, thus, did not seem to alter cell 
fate.  
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Figure 27: Re-expression of Mybl2 abrogates proliferation. (A) Growth of lineage negative 
enriched bone marrow cells form rtTA-M2 mice transduced with either a vector encoding for a 
specific Mybl2 shRNA and the inducible expression of Mybl2 (Mybl2/shRNA) or a vector only 
encoding for inducible expression of Mybl2 (Mybl2). The transduced cells were both cultured in 
presence (dox) and in absence (no dox) of doxycycline. Cell count was measured using the Cell 
Titer Glo luminescent cell viability assay. (B) Induced re-expression of Mybl2 in long term cultured 
cells with reduced Mybl2 levels (blue). Cell counting was performed using a Neubauer chamber. 
 Next, I asked whether long time cultured cells with reduced Mybl2 expression levels 
would also lose their proliferative capacity by induced re-expression of Mybl2. After about 
three weeks of cultivation, I took cells carrying the constitutive knockdown and the 
inducible Mybl2 cassette and induced ectopic Mybl2 expression. As the addition of 
1 µg/ml doxycycline had induced a tenfold overexpression of ectopic Mybl2 (3.2.2.2), I 
decided to test in parallel whether the addition of 25 ng/ml doxycycline would have the 
same effects. Again, the growth phenotype could be abrogated within a few days by re-
expression of Mybl2 using 1 µg/ml doxycycline (Figure 27 B, blue line). Although 25 ng/ml 
doxycycline were not enough to abrogate the growth phenotype, a slight inhibition of 
proliferation could be measured (Figure 27 B, turquoise line). This indicated that further 
testing for a dosage of doxycycline to induce a more physiological Mybl2 level would be 
necessary. Nevertheless, this experiment revealed the suitability of this system for gene 
expression analysis comparing cells with reduced levels of Mybl2 to cells where Mybl2 
had been re-expressed. Unfortunately, this experiment could not be repeated with the 
same results (data not shown). Despite several tries, the reason could not be identified.  
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3.3 Cell cycle-dependent gene expression by Mybl2 
 As I could not confirm the reversion of the growth phenotype associated with 
reduced Mybl2 expression levels by ectopic re-expression of wild-type Mybl2, I used an 
inducible Mybl2 knockdown approach in primary murine HSPCs immortalized by 
dominant-negative RUNX1 (Tsuzuki and Seto, 2012) for gene expression analysis. Thus, 
only gene expression differences with cell cycle phase-resolution induced by changes of 
the Mybl2 expression level will be measured.  
3.3.1 Venus-GMNN(1/110) in primary murine HSPCs immortalized by dominant-
negative RUNX1 
 A polyclonal cell line, derived from primary murine HSPCs immortalized by 
dominant-negative RUNX1 was used for the following experiments. First, the established 
Venus-GMNN(1/110) vector (3.1.3) was introduced into these cells. To enable a selection for 
transduced cells without cell sorting, the pVG lentiviral vector was modified to additionally 
encode for the expression of a hygromycin resistance (Figure 28, pVG-Hygro). After 
lentiviral transduction with the pVG-Hygro vector, the cells were selected for 10 days by 
hygromycin. Subsequently, the cells were transduced with a lentiviral vector encoding an 
inducible Mybl2 shRNA (Figure 28, pT6B-shRNA Mybl2/BFP). The Mybl2 shRNA was 
designed and tested in the laboratory in parallel to my experiments. Taking advantage of 
the M2-rtTA system (3.2.2) a lentiviral vector encoding for the doxycycline-inducible 
expression of this Mybl2 shRNA was produced. In order to visualize the induction of the 
Mybl2 shRNA flow cytometrically, the expression of a blue fluorescent protein (BFP) 
(Subach et al., 2011) was additionally encoded by the vector, also under the control of the 
inducible promoter. For selection of transduced cells, the vector encodes for a blasticidin 
resistance (Figure 28).  
 
Figure 28: Vector design for gene expression analysis in immortalized HSPCs. The pVG-
Hygro vector encoding for Venus-GMNN(1/110) and a hygromycin resistance gene, and the pT6B-
shRNA Mybl2/BFP vector encoding the inducible Mybl2 shRNA along with BFP and a constitutively 
expressed blasticidin resistance gene.  
Results 
66 
 
In order to induce the expression of the Mybl2 shRNA resulting in a reduced Mybl2 
expression level, doxycycline was added to one part of the described cell culture for 48 h 
(1 µg/ml). The cells without doxycycline treatment were used as control cells for the 
following PI-based re-analysis and gene expression analysis with cell cycle phase-
resolution. First, both cell cultures, with and without doxycycline treatment, were analyzed 
for their Venus-GMNN(1/110) expression by flow cytometry. Gaiting on the “live gate” (Figure 
29 A, P1), I determined four cell populations according to the Venus fluorescence intensity 
(Figure 29 B, P2-5) for cell sorting. 
 
Figure 29: Flow cytometry sorting of immortalized HSPCs according to the Venus 
fluorescence intensity. (A) “Live gate” (P1). (B) Sort gates according to the Venus fluorescence 
intensity used for PI-based re-analysis and Mybl2-dependent gene expression analysis. This figure 
shows the analysis of the immortalized HSPCs without doxycycline treatment (control cells). 
As in the experiments for the establishment of Venus-GMNN(1/110), the cell 
populations sorted for increased Venus fluorescence intensity (Figure 29 B, P2-5) each 
were enriched in a different cell cycle phase displaying a progress from the G1 to the G2 
phase with increasing Venus fluorescence intensity (Figure 30, A and B). The PI re-
analysis showed that the cells sorted for the P2 gate (Figure 29 B) were enriched in the 
G1 phase (Figure 30, A and B, P2 – G1) and cells sorted for the P3 gate (Figure 29 B) in 
the late G1/S phase (Figure 30, A and B, P3 – late G1/S). The P4 gate cell population 
(Figure 29 B) was mostly enriched in the S phase (Figure 30, A and B, P4 – S) and the P5 
cell population (Figure 29 B) in the late S/G2 phase (Figure 30, A and B, P5 – lateS/G2). 
This was true for immortalized HSPCs with and without induced Mybl2 shRNA. For both of 
these HSPC cultures, cells were sorted for the “live gate” to generate a control cell cycle 
profile (Figure 29 A; Figure 30, A and B, P1). 
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Figure 30: PI-based re-analysis of the immortalized HSPCs sorted according to the Venus-
GMNN(1/110) fluorescence intensity revealed a distinct cell cycle phase separation. (A) PI-
based re-analysis of the immortalized HSPCs without doxycycline treatment (control cells) sorted 
for the “live gate” and according to the Venus fluorescence intensity (Figure 29, A and B, P1-P5). 
(B) PI-based re-analysis of the immortalized HSPCs with reduced Mybl2 expression level sorted for 
the “live gate” and according to the Venus fluorescence intensity. 
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Importantly, PI-based re-analysis of the cells sorted for the “live gate” showed a 
regular cell cycle profile in both experimental groups (Figure 30, A and B, upper left, P1) 
demonstrating that the Venus-GMNN(1/110) expression did not alter the typical distribution 
of cells in each cell cycle phase. However, a difference in the cell cycle distribution 
between the two “live gate” cell populations (Figure 30, A and B, upper left, P1) had to be 
noted. While in the cell culture without doxycycline treatment about 70 % of cells were in 
the G1 phase and 22 % in the S phase (Figure 30 A, upper left), in the cells with reduced 
Mybl2 expression level 82 % were in the G1 phase and only 10 % in the S phase (Figure 
30 B, upper left). This could be due to changes in the cell cycle by reduced Mybl2 
expression levels, however, further measurements would be needed to support this 
finding. Also, the differences observed in the cell cycle distribution could be due to a day-
to-day variation in machine-settings, as FACS and PI-based re-analysis of cells with 
induced Mybl2 shRNA and without were performed on different days. This could 
additionally explain that the cells enriched for the late G1/S phase (P3) and the S phase 
(P4) enriched cells also differ slightly comparing cells with reduced Mybl2 level to the cells 
without. Cells with induced expression of the Mybl2 shRNA showed more cells in the G1 
and the G2 phase within the late G1/S phase enriched group, and more cells in G1 phase 
within the S phase enriched group compared to the control cells without doxycycline 
treatment. Gene expression analysis of typical cell cycle genes will reveal whether the 
enriched cell populations represent the correct cell cycle phase and can be compared to 
each other.  
In conclusion, an enrichment of cells in each cell cycle phase of cells with reduced 
Mybl2 expression levels and control cells was successfully accomplished and the sorted 
cell populations were used for gene expression analysis. 
3.3.2 Mybl2 dependent gene expression with cell cycle phase-resolution 
 Gene expression analysis was performed in the HSPCs immortalized by dominant-
negative RUNX1 separated into the different cell cycle phases by FACS (3.3.1) comparing 
cells with reduced Mybl2 expression levels to cells with a physiological Mybl2 expression 
level (control). For this analysis, I decided to focus on a specific set of genes including the 
candidate genes for the gene dosage-dependent tumor suppressor function of Mybl2 from 
prior microarray data (Heinrichs et al., 2013) and unpublished data). I chose to measure 
the expression levels of Aspm and Nusap1, as both genes are known to be important for 
spindle formation in mitosis, and Aspm possibly influences stem cell maintenance 
(Capecchi and Pozner, 2015; Li et al., 2016). Changes in their expression level upon 
reduced Mybl2 expression levels could indicate that they are relevant for the tumor 
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suppressor function of Mybl2. In addition, I compared these candidate target genes to 
genes that are well-characterized key Mybl2 target genes within the cell cycle, e.g. Foxm1 
and Ccnb1 (Sadasivam et al., 2012). I hypothesized that the key Mybl2 target genes 
important for cell cycle regulation would be less affected by reduced Mybl2 expression 
levels than the candidate genes that might be important for the tumor suppressor function 
of Mybl2. In addition, I expected that a cell cycle phase-resolution would reveal a more 
precise gene expression difference. Also, in order to ensure that the cell populations 
sorted according to the Venus fluorescence intensity reflected the correct cell cycle phase, 
I determined the expression level of the typical cell cycle marker genes used in 
establishing the Venus-GMNN(1/110) system: E2f1, Ccne1 and Dhfr.  
 First, I analyzed the Mybl2 expression level to validate that the induction of the 
expression of the Mybl2 shRNA had caused a Mybl2 knockdown in the immortalized 
HSPCs. Indeed, QRT-PCR analysis revealed a knockdown of Mybl2 to about 50 % 
expression level comparing cells sorted for the “live gate” with induced expression of the 
Mybl2 shRNA (Figure 31, P1, green bar) to the control (Figure 31, P1, grey bar). Further, 
evaluating the cell cycle distribution of the Mybl2 expression, it clearly showed a 
regulation within the cell cycle with an elevated expression in the S phase of cells with 
reduced expression level (Figure 31, green bars) as well as control cells (Figure 31, grey 
bars). The elevated expression in the S phase of the cell cycle is consistent with earlier 
reports about cell cycle phase distribution of Mybl2 expression (Lam et al., 1992). 
Interestingly, the Mybl2 expression level difference was greater between the cells 
enriched in the G1 and the late G1/S phase than in the S and late S/G2 phase comparing 
the cells with reduced Mybl2 to the control cells (Figure 31). This might indicate that in 
cells with reduced Mybl2 expression levels the cell cycle function of Mybl2 as a regulator 
of the transcription of genes required for the S/G2 phase progression is preserved. In 
contrast, genes regulated in the G1 phase could be strongly influenced by low levels of 
Mybl2.  
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Figure 31: Gene expression analysis of Mybl2 showed a 50 % knockdown and an elevated 
expression level during S phase. Gene expression of Mybl2 in immortalized HSPCs with and 
without induced Mybl2 shRNA sorted according to the Venus-GMNN(1/110) fluorescence intensity. 
Green bars indicate cells with Mybl2 knockdown, grey bars indicate control cells. The analysis 
verified the Mybl2 knockdown to 50 % expression level in cells with induced expression of the 
Mybl2 shRNA and showed Mybl2 regulation within the cell cycle with a peaking expression in the S 
phase. The greatest expression level difference between cells with reduced Mybl2 level and the 
control was seen in the G1 and the late G1/S phase. Measurements were performed in triplicates. 
Next, I analyzed whether the cell cycle marker genes (E2f1, Ccne1 and Dhfr) 
showed an elevated expression in their typical cell cycle phase. I expected that none of 
these genes would show expression differences upon Mybl2 gene-dosage changes. 
Surprisingly, E2f1 was the only typical cell cycle gene not affected by the reduced Mybl2 
expression level showing its normal cell cycle phase distribution with a peak in the G1 to 
late G1/S phase (Figure 32, upper left). Dhfr and Ccne1, however, showed a reduced 
expression level in cells with reduced Mybl2 expression, both to about 50 % expression 
level compared to the “live gate” sorted cells from the control (Figure 32, P1(dox) and P1). 
While Dhfr was mainly downregulated in the G1 and the late G1/S phase with almost the 
same expression levels as the control in the S and the late S/G2 phase, Ccne1 was 
downregulated significantly in every cell cycle phase except for the late S/G2 phase 
(Figure 32, bottom). Of note, Dhfr, in contrast to E2f1 and Ccne1, did not show its typical 
cell cycle phase distribution with an elevated expression in the S phase. This could be due 
to the Mybl2 gene-dosage changes. However, the greatest difference in the Dhfr 
expression level was found comparing the G1 and the late G1/S phase enriched groups, 
the late G1/S phase also being the group with the greatest difference comparing 
enrichment in PI-based re-analysis of cells with reduced Mylb2 expression level to 
controls (Figure 30). Thus, this difference in enrichment might account for the atypical 
distribution of Dhfr. However, Mybl2, also known to be elevated in S phase, showed its 
Results 
71 
 
typical distribution (Figure 31) indicating that the enriched phases represent the correct 
cell cycle phase. Of note, it is possible that the Dhfr expression level might show minor 
changes in cell cycle phase enrichment more sensitively.  
 
Figure 32: E2f1 expression is not affected by reduced Mybl2 expression levels, but Ccne1 
and Dhfr show reduced expression levels. Gene expression of typical cell cycle genes in 
immortalized HSPCs with and without induced Mybl2 shRNA sorted according to the Venus-
GMNN(1/110) fluorescence intensity. Green bars indicate cells with Mybl2 knockdown, grey bars 
indicate control cells. The analysis showed that only E2f1 is not affected by Mybl2 gene-dosage 
changes showing a regular distribution in the cell cycle phases. Ccne1 and Dhfr show reduced 
expression levels upon Mybl2 knockdown to 50 %. Measurements were performed in triplicates. 
In addition, I measured the gene expression of the two known Mybl2 target genes, 
Ccnb1 and Foxm1, expecting both to be largely unaffected. Also, the two candidate target 
genes, Nusap1 and Aspm, were analyzed.  
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Figure 33: Ccnb1, Foxm1, Nusap1 and Aspm show reduced expression levels upon reduced 
Mybl2 levels. Gene expression of Mybl2 candidate target genes in immortalized HSPCs with and 
without induced Mybl2 shRNA sorted according to the Venus-GMNN(1/110) fluorescence intensity. 
Green bars indicate cells with Mybl2 knockdown, grey bars indicate control cells. Analysis showed 
that all four genes have reduced expression levels upon Mybl2 knockdown to an expression level 
of 50 %. The downregulation was most obvious in the G1 and the late G1/S phase, while in the S 
and late S/G2 phase expression levels were close to normal, and in case of Ccnb1, Aspm and 
Nusap1 even slightly upregulated. Measurements were performed in triplicates.  
 Surprisingly, Ccnb1 and Foxm1 clearly showed a downregulation to 40 % and 60 % 
expression level upon reduced Mybl2 expression. The cell cycle phase distribution of both 
genes with an elevated expression in the G2 phase, however, remained intact. While 
Foxm1 also showed slightly reduced expression levels in the S and G2 phase, Ccnb1 had 
slightly elevated levels in these phases in the cells with reduced Mybl2 levels. Both genes 
showed the greatest expression difference comparing the G1 phases of cells with reduced 
Mybl2 to controls. The candidate genes, Aspm and Nusap1, were equally reduced upon 
Mybl2 shRNA expression. They showed a similar distribution upon Mybl2 knockdown in 
the cell cycle as Ccnb1, meaning strongly reduced expression levels in the G1 phase and 
slightly elevated expression levels in S and G2 phase.  
 Interestingly, not only key Mybl2 target genes, Ccnb1 and Foxm1, but also classical 
cell cycle genes, Ccne1 and Dhfr, and the candidate target genes, Aspm and Nusap1, 
were strongly influenced by Mybl2 gene-dosage changes. These findings indicate that a 
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reduced Mybl2 expression level might equally affect its target genes. Of note, the typical 
distribution of the candidate target genes and the peak phase expression in the cell cycle 
were not altered by reduced Mybl2 expression. However, comparing the sorted cell cycle 
phases of cells with reduced Mybl2 expression level to controls an expression difference 
can be measured with an especially strong effect comparing the G1 phases. This 
demonstrates that a cell cycle phase-resolution is important to detect Mybl2 gene-dosage 
dependent expression differences. The strong regulation of all genes comparing their 
expression level in the G1 phase could also suggest that this phase might be important for 
the tumor suppressor function of Mybl2. Of note, the G1 phase is described to be very 
important for cell fate decision (Capecchi and Pozner, 2015). My results point towards a 
tumor suppressor function of Mybl2 closely related to the cell cycle. The tested genes are 
strong candidate genes for the tumor suppressor function of Mybl2. Further studies 
building on my findings will reveal the mechanistic pathway for the tumor suppressor 
function of Mybl2.  
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4. Discussion 
 In my thesis I aimed to establish a cell cycle-readout suitable for cell cycle phase-
resolution of primary murine HSPCs with an RNAi-mediated Mybl2 knockdown to 30 -
 50 % expression level in vitro. Gene expression analysis of surrogate Mybl2 target genes 
in these cells were sought to reveal a mechanistic insight into the recently discovered 
function of Mybl2 as a sub-haploinsufficient tumor suppressor in MDS (Heinrichs et al., 
2013).  
4.1 Establishment of a cell cycle-readout 
 The establishment of a cell cycle-readout allowing for an undisturbed cell cycle 
progression and an unperturbed enrichment of cells in the different cell cycle phases by 
flow cytometry was successfully accomplished in human and murine hematopoietic cells 
using Venus-GMNN(1/110) as a single cell cycle indicator. Notably, the originally planned 
implementation of the Fucci2 technique (Sakaue-Sawano et al., 2011) revealed several 
difficulties, especially concerning the use of the CDT1(30/120) fusion protein as the G1 
phase indicator. Specifically, the replacement of mCherry in mCherry-CDT1(30/120) by 
DsRed-Express2 (RFP) (Strack et al., 2008) or mTurquoise2 (Tq) (Goedhart et al., 2012) 
resulted either in a continuous expression of the CDT1(30/120) fusion protein throughout the 
whole cell cycle or in the silencing of its expression (3.1.2). 
 To address the difficulties faced while establishing the Fucci2 technique, I focused 
on the modifications I had chosen to implement in order to create an improved version of 
Fucci2. In the first “Fucci” study, Hela cells had been cotransduced with two vectors, each 
encoding one cell cycle indicator (Sakaue-Sawano et al., 2008). I recorded the same 
difficulties with the CDT1(30/120) fusion protein in cells transduced with one vector encoding 
for both cell cycle indicators and cells sequentially transduced with two separate vectors, 
each encoding for one cell cycle indicator (3.1.2). Therefore, the differences in the 
transduction process are unlikely to account for the observed difficulties with the 
CDT1(30/120) fusion protein. Further, in parallel to my experiments, the Fucci technique has 
been established using only one vector suitable for cell culture and mice (Koh et al., 2017; 
Mort et al., 2014). Yet, another difference in my experiments was that I used the DNA 
sequences of mCherry-CDT1(30/120) and Venus-GMNN(1/110) from the original paper for the 
vectors, but exchanged the linker sequence designed to facilitate cloning steps by a 
glycine linker. Since the glycine linker did not alter the function of Venus-GMNN(1/110) as 
the G2 phase indicator, this change in sequence is also very unlikely to account for the 
difficulties faced with the CDT1(30/120) fusion protein. The most obvious modification, 
however, was the change of fluorochromes. The fluorochromes RFP and Tq allowing for 
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measurements on flow cytometers not equipped with a yellow-green laser might be 
unsuitable for a fusion to CDT1(30/120), a protein tightly regulated in the cell cycle by 
Ubiquitin-induced degradation (Nishitani et al., 2004). Especially the RFP-CDT1(30/120) 
fusion protein might predispose to accumulation in the cell due to the size of RFP as 
tetrameric protein inhibiting a quick and complete degradation after the G1 phase (Strack 
et al., 2008). However, the fusion protein of CDT1(30/120) and the monomeric Tq showed 
the same problem of continuous expression throughout the cell cycle. Further, the flow 
cytometric analysis of the fusion protein of CDT1(30/120) and another monomeric 
fluorochrome originating from a different structural fluorochrome background, mTagBFP 
(Subach et al., 2011), likewise suggested a continuous expression throughout the cell 
cycle (data not shown). In addition, I eventually tested the performance of the original 
fusion protein mCherry-CDT1(30/120) and the flow cytometric analysis confirmed the 
difficulties observed with the other fluorochromes (data not shown). Reassuringly, the 
original “Fucci” study already reported difficulties replacing mKO2 by fusing CDT1(30/120) to 
mRFP1 or mAG reporting a continuous expression throughout the cell cycle (Sakaue-
Sawano et al., 2008). Interestingly, while this first Fucci study introducing mKO2-
CDT1(30/120) remains unclear about the use of single cell clones in order to receive stable 
transformants, the improved version, Fucci2, successfully introducing mCherry for the 
CDT1(30/120) fusion protein established stable transformants by single cell cloning (Sakaue-
Sawano et al., 2011). Most likely, observing that a high expression level of Tq-CDT1(30/120) 
or RFP-CDT1(30/120) led to cell death (3.1.2.2), a high expression level of CDT1 might be 
toxic for cells. Indeed, the experimental cancer drug MLN4924, inhibiting cullin-RING E3 
ubiquitin ligases, was shown to induce DNA rereplication and cell apoptosis mediated by 
elevated levels of CDT1 (Lin et al., 2010). This is consistent with early reports about 
overexpression of CDT1 causing rereplication of DNA (Blow and Dutta, 2005; Vaziri et al., 
2003). The high-expression levels of the G1 phase indicator probably exceeded the 
ubiquitination capability of the responsible E3 ligase resulting in the continuous expression 
observed. Thus, the cell cycle-dependent expression of the CDT1(30/120) fusion protein 
might only work in cells with a low expression level. In my experiments, the expression of 
the CDT1(30/120) fusion protein was under control of the SFFV promoter. This promoter 
might have been too potent especially used in hematopoietic cells. However, when 
exchanged for the less potent CMV promoter the expression of the CDT1(30/120) fusion 
proteins was still cell cycle phase-independent (data not shown).  
 These findings suggest that in a cell culture derived from a single cell clone having a 
tolerable expression level of the CDT1(30/120) fusion protein, the G1 phase indicator 
possibly labels cells correctly. A clonal selection of cells might also reveal single cells with 
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a cell cycle-dependent expression of RFP-CDT1(30/120) or Tq-CDT1(30/120). Of note, Venus-
GMNN(1/110) did not need a single cell clone in order to be degraded in a cell cycle-
dependent manner. 
 In the beginning of my experiments, Fucci had neither been used in hematopoietic 
cell lines nor in primary hematopoietic stem and progenitor cells. Although there are no in 
vitro implementations of Fucci in hematopoietic cells up to date, recently, transgenic mice 
expressing Fucci fluorescent cell cycle probes (Sakaue-Sawano et al., 2008) have been 
used to analyze the cell cycle in hematopoietic cells (Sakaue-Sawano et al., 2013; Shand 
et al., 2014; Tomura et al., 2013; Yo et al., 2014). Interestingly, already the selection of 
mice revealed difficulties, as only some mice expressed Fucci in hematopoietic cells at a 
sufficient level and often very low expression levels were faced. New mouse lines of Fucci 
have been created continuously as reports show problems with transgene inactivation and 
varying expression levels in several tissues (Abe et al., 2013; Mort et al., 2014), mirroring 
the problems I encountered during the implementation of the Fucci2 technique. Of note, 
while the GMNN(1/110) cell cycle indicator was interchangeable between species, different 
versions of the truncated CDT1 have been reported for zebrafish and fly, although cell 
cycle regulation is usually highly conserved among species. Again, the problem with the 
CDT1(30/120) fusion protein was a constant expression throughout the cell cycle (Sugiyama 
et al., 2009; Zielke et al., 2014). In addition, there have been different ways of interpreting 
the results of cells isolated from Fucci mice. Double-negative cells expressing Fucci are 
most often accounted to be in the very early G1 phase as cells lose expression of either 
marker right after division and need some time for the accumulation of mCherry-
CDT1(30/120) (Jovic et al., 2013). Of note, in lymphocytes double-negative cells were 
interpreted as not expressing the indicators (Tomura et al., 2013). Indeed, the double-
negative cells in my study could be cells in the early G1 phase due to a rapidly cycling cell 
population. However taking this into account, it is surprising that testing the RFP- and Tq-
CDT1(30/120) fusion protein in the same OCI-AML2 cell line the amount of double-negative 
cells as well as RFP or Tq positive cells was not the same. Whether double-negative cells 
represent an early G1 phase could have been tested by sorting the double-negative cells 
and analyzing them again after a certain time in cell culture to see if they become RFP or 
Tq positive with progression of G1 phase. Importantly, even if the double-negative cells 
could be accounted as early G1 phase cells and were labeled correctly, the continuous 
expression of the CDT1(30/120) fusion protein in the G2 phase would still prohibit a correct 
cell cycle phase separation in my experiments.  
 In conclusion, the cell cycle separation of hematopoietic cells in vitro only using the 
GMNN(1/110) fusion protein is an easy and reproducible way of unperturbed cell cycle 
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phase separation for gene expression analysis. In need of two cell cycle indicators single 
cell clones or the use of hematopoietic cells from Fucci mice would offer a practical 
solution. Also, testing a murine version of CDT1 for separation of murine cell lines or 
search for a replacement of CDT1 would be reasonable. Most recently, a completely 
revised version, Fucci4, has been published (Bajar et al., 2016) introducing the first 
version visualizing every cell cycle phase and the transitions, additionally allowing to 
refrain from the CDT1(30/120) marker. 
4.2 Clonal dominance of HSPCs in vitro by reduced Mybl2 expression levels 
 In my study, I could show that lin.-neg. enriched murine bone marrow cells with an 
RNAi-mediated Mybl2 knockdown show clonal dominance and a proliferative advantage in 
vitro. Thus, a Mybl2 expression level of 30 - 50 % immortalized primary murine HSPCs. 
The observed growth phenotype could be abrogated by re-expression of ectopic Mybl2 
within a few days demonstrating the dependency of the immortalized cells on reduced 
Mybl2 levels. Unfortunately, this observation could not be reproduced in further 
experiments.  
 While in vivo two different Mybl2 shRNAs were successfully leading to clonal 
dominance of murine HSPCs (Heinrichs et al., 2013), only one of those shRNAs could be 
used to immortalize murine HSPCs in vitro. Also, the ectopic re-expression of Mybl2 could 
not consistently abrogate the growth phenotype by a reduced Mybl2 expression level. It is 
well known that the ectopic re-expression of a gene can be challenging. A key 
requirement for such a re-expression experiment is that the immortalized HSPCs in vitro 
constantly depend on reduced Mybl2 levels. Taking this into account, the time point of the 
re-expression in culture is most likely very important. While an early passage of cells 
might still be dependent on the on-target effect of the Mybl2 shRNA, thus, the reduced 
Mybl2 expression level, acquisition of further mutations may lead to growth advantages 
due to possible off-target effects of reduced Mybl2 level. In a genome wide analysis of the 
efficacy and specificity of siRNA-mediated gene silencing it has been shown that partial 
sequence identity of the siRNA sequence to a non-target sequence can mediate strong 
off-target effect (Jackson et al., 2003). These off-target effects are due to miRNA-like 
binding effects that lead to the simultaneous binding of one miRNA to various target 
mRNAs (Lim et al., 2005). Such effects are unpredictable, and most off-target effects are 
disadvantageous for cell growth and survival, thus, rarely lead to clonal expansion. In this 
study however, most likely, an advantageous combination of a positive on-target effect by 
the Mybl2 shRNA with a collaborating positive off-target effect is the reason for the Mybl2 
independent expansion in vitro. This is supported by the fact that in parallel to my thesis, 
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experiments have shown that an inducible RNAi system for Mybl2 using a miRNA-derived 
shRNA expression vector could not immortalize primary HSPCs on its own (Heinrichs 
Lab, unpublished). To which extend, however, the off-target effect supports cell expansion 
in vitro remains to be determined. Also, although taking great care planning the 
experiments, experimental settings, integration problems with the vector or varying levels 
of reduced Mybl2 could have prohibited a successful reproduction of the Mybl2 re-
expression experiment in vitro.  
4.3 Cell cycle-dependent gene expression analysis 
 Cell cycle-dependent gene expression analysis in primary murine HSPCs 
immortalized by dominant-negative RUNX1 revealed reduced expression levels of Mybl2 
and possible target genes upon a Mybl2 knockdown to about 50 % expression level. The 
classical Mybl2 target genes, Ccnb1 and Foxm1, as well as Aspm, Nusap1, Ccne1 and 
Dhfr were found to be regulated by Mybl2. The largest expression differences between 
cells with reduced Mybl2 expression and controls were observed in the G1 phase. The 
typical cell cycle phase distribution of the target genes and the peak phase expression in 
the cell cycle were not altered by reduced Mybl2 expression.  
 PI-based re-analysis of immortalized HSPCs after FACS according to the Venus-
GMNN(1/110) fluorescence intensity revealed slight differences in data acquired on different 
days. This demonstrated that minor changes due to day-to-day variations in machine and 
staining parameters can have a significant impact on resolution and enrichment of cells in 
each phase. Performing the flow cytometric experiments used for gene expression 
analysis on the same day could improve the comparability between sorted cell 
populations. Further, a second dimension, ideally a different G1 phase indicator than 
CDT1(30/120) might strongly improve robustness of the demonstrated sorting approach. 
Recently, with the introduction of “Fucci4” an alternative G1 phase marker (SLBP18-126) 
was published (Bajar et al., 2016). In addition, talking about comparability of gene 
expression between the cells sorted for different cell cycle phases, the type of 
housekeeping genes used have to be taken into account. As gene expression analysis is 
normalized to the expression of housekeeping genes, the stability of housekeeping gene 
expression in different phases is very important. To rule out expression level differences 
induced by instable housekeeping genes, I used 3 different ones, none of which is known 
to be cell cycle-regulated. 
 Originally, I hypothesized that target genes of Mybl2 could be divided into two 
groups: One set of target genes would have low affinity binding sites and would be 
possibly responsible for the tumor suppressor function, which is gene-dosage dependent. 
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In contrast, another set of target genes responsible for the cell cycle regulation would 
have high affinity binding sites. The target genes with high affinity binding sites were 
sought to be largely unaffected by reduced Mybl2 expression levels. However, the gene 
expression data suggests that at least the target genes analyzed here were equally 
affected pointing towards overall gradual effects on all target genes. Thus, a differential 
effect (core functionality vs. tumor suppressor activity of Mybl2) could result from reaching 
threshold expression levels of specific downstream target genes. This relies on the fact 
that small changes can have a strong biological impact if the gene expression level of a 
specific gene is close to the threshold level affecting its biological function. Thus, 
especially the cell cycle related gene expression changes are likely to result in 
proliferation or influence cell fate decision as most cell cycle genes are regulated very 
tightly within the cell cycle. It is important to notice that protein levels play a great role in 
the cell cycle and many pathways are regulated via protein ubiquitination rather than only 
gene expression. Western blots of Mybl2 and its target genes would further support the 
gene expression findings in this study on the protein level.  
 Interestingly, I could show that Mybl2 gene-dosage modification influences the 
expression of Aspm, Ccne1 and Nusap1. Aspm has been shown to be necessary for 
maintenance of symmetric progenitor cell division in mice. Further, it was recently found 
that Aspm protects Ccne1 from ubiquitination (Capecchi and Pozner, 2015). In the same 
study, in Aspm homozygous mutant mice, the cell cycle progression was found to be 
Ccne1-dependent, while mitotic cleavage orientation was Ccne1 independent. Ccne1 
itself is described to be regulated by an E2f-dependent mechanism. My data suggests that 
Ccne1 is an important gene to follow-up as it might be regulated via an E2f1 induced 
Mybl2-Aspm pathway. Interestingly, Ccne1 downregulation provided HSCs with a 
competitive advantage in bone marrow transplantation experiments (Campaner et al., 
2013). Further, Ccne1 is also described to have a function in S phase and mitotic 
progression (Capecchi and Pozner, 2015), just as Mybl2. These facts along with the 
finding that Mybl2 influences gene expression levels of Aspm and Ccne1 suggest a role 
for Mybl2 in symmetric versus asymmetric stem cell division. The Mybl2 induced 
regulation of Nusap1, known to regulate spindle formation in mitosis and microtubule 
oscillation (Li et al., 2016), further supports this notion.  
4.4 Outlook 
 This work showed that Venus-GMNN(1/110) as a single cell cycle indicator could be 
used successfully for enrichment of cells in different cell cycle phases for Mybl2 gene-
dosage dependent gene expression analysis in immortalized HSPCs. My data suggested 
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that all Mybl2 target genes were equally affected by downregulation of Mybl2 expression, 
depending on the cell cycle phase. This could be revealed for Ccnb1, Foxm1, Aspm, 
Nusap1, Dhfr and Ccne1. The Mybl2-dependent regulation of the cell cycle genes Foxm1, 
Ccnb1 and Ccne1 strongly suggests a central role of the tumor suppressor function of 
Mybl2 in the cell cycle. The newly discovered regulation of Aspm and Nusap1 possibly 
points towards an additional role of Mybl2 in cell fate decision in HSPCs. Further studies 
building on my findings on the cell cycle-dependency of Mybl2‟s transactivation function 
will support to define the Mybl2 driven tumor suppressor pathway. Improvements for 
following experiments should consider introducing a second dimension, i.e. a different G1 
phase marker than CDT1(30/120), for robustness of the cell cycle phase separation. 
Additionally, analyzing the immunophenotype and the changes of distribution of cells in 
the cell cycle phases upon reduced Mybl2 levels would reveal an even better idea of 
Mybl2 induced changes in HSPCs. To gain a deeper understanding of Mybl2 regulation of 
the target genes, western blot analysis would demonstrate how changes in the gene 
expression analysis translate to the protein level. Microarray-based global gene 
expression analysis of the cells with reduced Mybl2 expression levels separated into the 
cell cycle phases will help to identify further target genes important for the tumor 
suppressor function of Mybl2. The implementation of my results and their advancement by 
the mentioned techniques will reveal a mechanistic insight into the tumor suppressor 
function of Mybl2, which will hopefully reveal new therapeutic targets for patients suffering 
from MDS.  
. 
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5. Summary 
 MYBL2 has been identified as a dosage-dependent tumor suppressor in 
myelodysplastic syndromes (MDS). The gene is ubiquitously expressed and encodes a 
transcription factor which is strictly required for cell cycle progression. Of note, 
downregulation of Mybl2 expression levels to 30 - 50 % (sub-haploinsufficiency) provides 
a clonal advantage to hematopoietic stem and progenitor cells in vivo. Yet, the molecular 
mechanism of this phenotype is unknown. In this thesis, I aimed to identify Mybl2 
candidate target genes responsible for its tumor suppressor function by analyzing Mybl2-
dependent gene expression differences at the cell cycle phase level in murine 
hematopoietic stem and progenitor cells. Here I show that RNA interference-mediated 
knockdown of Mybl2 to sub-haploinsufficient levels allows freshly isolated hematopoietic 
stem and progenitor cells to proliferate and expand in vitro. The re-expression of wild type 
Mybl2 abrogated the growth of these cells within a few days. Unfortunately, the reversion 
of the growth phenotype could not be reproduced consistently. As a consequence, for 
gene expression analysis I used an inducible Mybl2 knockdown approach in murine 
hematopoietic stem and progenitor cells that were immortalized with dominant-negative 
RUNX1. Additionally, I established the expression of a cell cycle phase-dependent 
indicator protein (Venus-GMNN(1/110)) that allowed the undisturbed separation of cells at 
the different cell cycle phases by flow cytometry. I exploited the combination of the 
inducible Mylb2 knockdown and the Venus-GMNN(1/110)-based cell cycle phase separation 
to identify candidate target genes affected by reduced levels of Mybl2. The well-
established Mybl2 target genes, Cyclin B1 (Ccnb1) and Foxm1, showed a significantly 
reduced expression upon Mybl2 downregulation even without cell cycle phase-resolution. 
In addition, my results demonstrated that the expression levels of Aspm and Nusap1, two 
genes important for spindle formation during mitosis, were influenced by Mybl2. I could 
also show that the expression levels of Cyclin E (Ccne1) and Dhfr, two classical cell cycle 
regulatory genes, were reduced upon low expression levels of Mybl2. Comparing the cells 
with reduced Mybl2 expression level and controls sorted for the different cell cycle phases 
the strongest expression differences were determined comparing the G1 phases. My data 
confirmed Cyclin B1 and Foxm1 as Mybl2 target genes and newly identified Aspm, 
Nusap1, Dhfr and Cyclin E as regulated upon Mybl2 gene-dosage changes. These 
findings point towards a role of these genes in a cell cycle-related tumor suppressor 
function of Mybl2 and, for instance the regulation of Aspm, towards a possible role of 
Mybl2 in cell fate decision.  
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6. Zusammenfassung 
 MYBL2 ist ein dosis-abhängiger Tumorsuppressor in Myelodysplastischen 
Syndromen. Dieses Gen ist ubiquitär exprimiert und kodiert einen Transkriptionsfaktor, 
der unabdingbar für den Ablauf des Zellzyklus ist. Die Verminderung der Mybl2 
Expression auf 30 - 50 % des Normallevels führt jedoch zu einem klonalen 
Expansionsvorteil hämatopoetischer Stamm- und Vorläuferzellen in vivo. Die 
Komponenten des molekularen Mechanismus dieses Phänotyps sind bisher völlig 
unbekannt. Ziel dieser Arbeit war es Kandidatengene, die maßgeblich an der 
Tumorsuppressorfunktion von Mybl2 beteiligt sind, mittels zellzyklusaufgelöster 
Genexpressionsanalysen zu identifizieren. Zunächst konnte ich zeigen, dass frisch 
isolierte murine hämatopoetische Stamm- und Vorläuferzellen durch einen RNA-
Interferenz-vermittelten Knockdown von Mybl2 auf 30 - 50 % auch in vitro einen 
Expansionsvorteil haben. Die ektopische Expression von Wildtyp Mybl2 konnte diesen 
Expansionsvorteil in kurzer Zeit aufheben. Leider ließ sich dieses Ergebnis nicht konstant 
reproduzieren. Für die geplanten Genexpressionsanalysen nutzte ich daher die 
Induzierbarkeit eines RNA-Interferenz vermittelten Mybl2 Knockdowns in murinen 
hämatopoetischen Stamm- und Vorläuferzellen, die mittels dominant-negativem RUNX1 
immortalisiert wurden. Zusätzlich habe ich die Expression eines zellzyklusregulierten 
Indikatorproteins (Venus-GMNN(1/110)) in hämatopoetischen Zellen etabliert, welche die 
durchflusszytometrische Trennung von Zellpopulationen entsprechend der einzelnen 
Zellzyklusphasen erlaubt. Die Kombination dieser beiden Systeme habe ich genutzt, um 
mittels Genexpressionsanalysen Targetgene von Mybl2 zu identifizieren, die durch 
Verminderung des Mybl2 Expressionslevels unterschiedlich reguliert werden. Die bereits 
etablierten Mybl2 Targetgene, Cyclin B1 (Ccnb1) und Foxm1, zeigten schon ohne 
Beachtung der Zellzyklusauflösung ein deutlich herabgesetztes Expressionslevel. 
Weiterhin war die Expression von Aspm und Nusap1, zwei Gene, die wichtig für die 
Formation der Mitosespindel sind, ebenfalls stark von reduzierten Mybl2 
Expressionsleveln betroffen. Auch die Expression von Cyclin E und Dhfr, zwei klassischen 
Regulatoren des Zellzyklus, war in Zellen mit Verminderung des Mybl2 Expressionslevels 
deutlich erniedrigt. Die Genexpression im Vergleich der einzelnen Zellzyklusphasen 
zeigte, dass insbesondere die Expression in der G1 Phase bei allen Mybl2 Targetgenen 
vermindert ist. Meine Arbeit bestätigte Cyclin B und Foxm1 als Mybl2 Targetgene, zeigte 
aber auch, dass die Expression von Aspm, Nusap1, Dhfr und Cyclin E stark von Mybl2 
Gendosisveränderungen betroffen war. Dies lässt zum einen eine Funktion dieser Gene in 
einer zellzyklusnahen Tumorsuppressorfunktion von Mybl2 vermuten, andererseits weist 
die Regulation, zum Beispiel von Aspm, auf eine mögliche Beteiligung von Mybl2 an der 
Zellschicksalsentscheidung hin.  
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Ccnb1-FW1 TGCAGTGAGTGACGTAGACGCAGAT 
Ccnb1-RV1 CCAGTCACTTCACGACCCTGTAGGT 
Ccne1-FW1 AGGAAGGCAAATGTGGCCGTGTT 
Ccne1-RV1 TGAAAGAGCAGGGGTCCACGCAT 
Dhfr-FW1 ACCAGGCCACCTCAGACTCTTTGT 
Dhfr-RV1 ACCTCAGAGAGGACGCCTGGGTAT 
E2f1-FW1 GATGCCCACCTGTCTGCAGCTTT 
E2f1-RV1 ATGTGGCAGCAACCAAACCCCAG 
Foxm1-FW1 AGCTAAGGGTGTGCCTGTTCCCA 
Foxm1-RV1 TGGTTAAGCTGTTGTCCAGCGTGC 
hPGKpro-FW1 GCACATTCTTCACGTCCGTTC 
hPGKpro-RV1 CAAGGAACCTTCCCGACTTAGG 
Mybl2-FW1 ATCCACTCCAGTGTGTAGCCAAA 
Mybl2-RV1 CCATGGAGTACTTCTGATCTGGG 
Mybl2-FW6 TGGGTACAGCTTTGCCCTGTGAGT 
Mybl2-RV6 GGCCCAAGCCAAGTGCGTTATGA 
Ubql1-FW1 GCACCTAGCACTGCACCTAGTGA 
Ubql1-RV1 TGAAATCTGACTTCTGGACTCTGC 
Vps39-FW1 GAGGAGAAGGTGTGCATGGTATG 
Vps39-RV1 GGTGTCGGCTGAGTTTACCTCTT 
Ywhaz-FW1 TGAAGAGTCGTACAAAGACAGCACGC 
Ywhaz-RV1 CAGACAAAGGTTGGAAGGCCGGT 
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PCR oligonucleotides: 
Oligoname Sequence (5„ to 3„) 
C-CDT1-FW1 TCCATCACACTGGCGGCCGCTCGAGCCCAGCCCCGCCAGGCCCG 
C-CDT1-FW2 GGACGAGCTGTACAAGGGCGGAGGACCCAGCCCCGCCAGGCCC 
C-CDT1-FW3 CCACCACCTGTTCCAGGGCGGAGGACCCAGCCCCGCCAGGCCCG 
C-CDT1-FW4 GGATCTAGGGGCGGAGGACCCAGCCCCGCCAGGCCCG 
C-CDT1-RV1 CCGATACGCGTTTAGATGGTGTCCTGGTCCTGC 
C-Fucci2-FW1 GGCATGGACGAGCTGTACAAGGGATATCCATCACACTGGCGGCC 
C-GMNN-FW1 
TCCATCACACTGGCGGCCGCTCGAGATGAATCCCAGTATGAAGCAG
AAACAA 
C-GMNN-FW2 
GGACGAGCTGTACAAGGGCGGAGGAAATCCCAGTATGAAGCAGAA
ACAAGAA 
C-GMNN-RV1 CCGATGGTACCTTACAGCGCCTTTCTCCGTTTTTCTGC 
C-mCherry-FW1 CGCTGGAATTCGCCACCATGGTGAGCAAGGGCGAGGA 
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C-RFP-RV1 CCCGCCACCACCTGTTCCAG 
C-Venus-FW1 CGCTGGGATCCGCCACCATGGTGAGCAAGGGCGAGGA 
C-Venus-RV1 CTTGTACAGCTCGTCCATGCC 
mTurquoise2 FW1 CGCTGTCTAGAGCCACCATGGTGAGCAAGGGCGAGGA 
mTurquoise2 RV1 GGGATCCACCGGATCTAGGGGCGGAGGA 
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bp base pair 
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CD Cluster of differentiation 
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CDS Coding sequence 
Cdt1 Chromatin licensing and DNA replication factor 1 
CHIP Clonal hematopoiesis of indeterminate potential 
CK1α Casein kinase 1α 
CKI Cyclin-dependent kinase inhibitor 
cm centimeter 
CMV Cytomegalovirus 
CRBN Cereblon 
Ctrl. Control 
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d days 
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Dhfr dihydrofolate reductase 
DMEM Dulbecco's modified Eagle medium 
DMSO Dimethylsulfoxide 
DNA Desoxyribonecleic acid 
dNTP Desoxyribonukleosidtriphosphates 
Dox Doxycycline 
DPBS Dulbecco‟s Phosphate-Buffered Saline 
e.g. exempli gratia 
E2f1 E2F transcription factor 1 
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et al. et alia 
etc. et cetera 
FAB French-American-British 
FACS Fluorescence activated cell sorting 
FBS Fetal bovine serum 
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Foxm1 Forkhead box M1 
FSC forward scatter 
FW Forward (primer) 
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GFP  green fluorescent protein 
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h hours 
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HIV-1 Human immunodeficiency Virus-1 
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i.e. id est 
IL-3 Interleukin 3 
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M/mM Molar/millimolar 
MA Massachusetts 
MACS Magnetic activated cell sorting 
MDS Myelodysplastic syndromes 
mFlt3 ligand murine Fms-like tyrosine kinase 3 ligand 
mg milligram 
Mg
2+
 Magnesium 
MgCl Magnesium chloride 
MGUS monoclonal gammopathy of undetermined  
min  minute 
miRNA microRNA 
ml milliliter 
MO Missouri 
MPN Myeloproliferative neoplasm 
mRNA messenger ribonucleic acid 
MSC Myelodysplastic stem cell 
mScf murine stem cell factor 
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Mybl1 MYB like 1 
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RNAi RNA interference 
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RT Reverse transcriptase 
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% Percent 
3„/ 5„ 3 prime/ 5 prime (UTR) 
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